1 **Full title:**

2 Triazole ureas covalently bind to strigolactone receptors and regulate signaling

3 **Running title:**

4 Covalent regulators of strigolactone

5

6 **Authors**

7 Hidemitsu Nakamura,^{1†} Kei Hirabayashi,^{1†} Takuya Miyakawa,¹ Ko Kikuzato,¹ Wenqian
 8 Hu,¹ Yuqun Xu,¹ Kai Jiang,¹ Ikuo Takahashi,¹ Naoshi Dohmae,² Masaru Tanokura,¹
 9 Tadao Asami,^{1,3*}

10

11

12 **Affiliations**

13 ¹ *Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1*
 14 *Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan*

15 ² *Biomolecular Characterization Unit, RIKEN Center for Sustainable Resource Science,*
 16 *Wako, Saitama, Japan*

17 ³ *Department of Biochemistry, Faculty of Science, King Abdulaziz University, P.O. Box*
 18 *80203, Jeddah 21589, Saudi Arabia*

19

20 ***Corresponding author. Email: asami@mail.ecc.u-tokyo.ac.jp (T.A.)**

21 [†]These authors contributed equally to this work.

22

23

24

25 **Abstract**

26 Strigolactones (SLs), a class of plant hormones with multiple functions, mediate plant-plant and
 27 plant-microorganism communications in the rhizosphere. In this study, we developed potent
 28 strigolactone antagonists, which covalently bind to the strigolactone receptor D14, by preparing
 29 an array of triazole urea compounds. Using yeast two-hybrid assays and rice tillering assays, we
 30 identified a triazole urea compound KK094 as a potent inhibitor of strigolactone receptors. The
 31 LC-MS/MS analysis and X-ray crystallography concluded that KK094 was hydrolyzed by D14,
 32 and that a reaction product of this degradation covalently binds to the Ser residue of the catalytic
 33 triad of D14. We also identified KK052 and KK073, whose effects on D14–D53/D14–SLR1
 34 complex formation were opposite due to a trifluoromethyl group on its benzene ring. These
 35 results demonstrate that triazole urea compounds are potentially powerful tools for agricultural
 36 application and may be useful for the elucidation of the complicated mechanism underlying SL-
 37 perception.

38
 39

40 MAIN TEXT

41 42 Introduction

43 Strigolactones (SLs) are a class of plant hormones that control many aspects of plant growth and
44 development. They promote the efficiency of arbuscular mycorrhizal symbiosis and the
45 germination of parasitic plants of the Orobanchaceae family in the rhizosphere (1). Therefore,
46 chemical regulators of SL functions might ultimately achieve widespread use in agricultural
47 applications (2). To date, SL mimics have been developed to inhibit branching (2, 3) and trigger
48 suicidal germination of parasitic weeds, and some compounds have succeeded in generating
49 practical treatments that can induce suicidal germination of parasitic weeds in soil (4), and
50 recently, several groups have reported the development of SL antagonists (5–9).

51 Important factors for SL perception and signaling have been identified using SL mutants
52 (10), including those of D14, an α/β hydrolase (ABH) (11, 12), D3/MAX2 (13, 14), an F-box
53 protein, and D53/SMXLs (15–17). It was recently postulated that SL is received by D14, which
54 forms a complex with D3/MAX2 and D53/SMXLs (16, 17). This interaction stimulates the
55 degradation of SL signaling inhibitors, including D53/SMXLs, which promotes the assembly of
56 the TOPLESS corepressor-nucleosome complex (18), and enhances the expression of SL-
57 inducible genes. Once SL is received by D14, it is hydrolyzed by D14 and a cleaved D-ring
58 fragment is produced (12, 19). Recently, the D-ring-derived cleaved fragment was reported to
59 form a covalent bond with a His residue in the catalytic center of D14 (19, 20). The formation of
60 the D14-covalently linked intermediate molecule (CLIM) complex induces a dramatic change in
61 the conformation of D14 and the formation of the D14–D3/MAX2 complex, which is essential for
62 SL signaling (21). In addition, the SL hydrolysis of D14 is also required for the complex
63 formation directly with D53/SMXLs (16, 17) and another target SLR1 (19), which is a negative
64 regulator of gibberellin signaling. However, the mechanism of their SL-dependent interactions
65 remains unclear.

Therefore, the blockade of the hydrolytic activity of D14 is a promising approach for the development of SL signaling inhibitors. D14 is an ABH, which belongs to a serine-hydrolase family. Serine-hydrolases universally possess a nucleophilic Ser-residue in their active sites, which is used for hydrolysis of their substrates. This nucleophilicity can be a target for covalent modification by reactive electrophiles. Indeed, wide-ranging types of electrophiles, including β -lactams/ β -lactones, fluorophosphonates, and carbamates covalently modify the Ser-residue of target proteins (22). The tetrazole urea LY2183240-induced inhibition occurred via covalent carbamylation of the serine nucleophile of FAAH (23). In addition, an isoxazolonyl urea and a 1,2,4-triazole urea were potent inhibitors of serine hydrolases (24, 25). These reports suggest that *N*-heterocyclic ureas, which can attack the nucleophilic Ser-residue in active sites of their targets, are a potent scaffold for serine hydrolase inhibitor design. Adibekian et al. synthesized a variety of 1,2,3-triazole ureas using click chemistry and determined that they selectively inhibit enzymes from diverse branches of the mammalian serine hydrolase family (26).

Here, we report that some 1,2,3-triazole ureas can inhibit the hydrolytic activity of the SL receptor D14 and stimulate rice tillering by blocking SL signaling. We also showed that D14 could degrade KK094, a potent 1,2,3-triazole urea D14-inhibitor. Using LC-MS/MS analysis and X-ray crystallography, we further confirmed that a reaction product of this degradation covalently binds to the Ser residue of the catalytic triad of D14. We also identified KK052 and KK073, whose effects on D14–D53 complex formation were opposite due to the presence or absence of trifluoromethyl group on the benzene ring. These compounds may have a potential as a useful tool to deepen our understanding of the molecular mechanism underlying SL-perception.

Results

91 **Synthesis and selection of candidate compounds for SL-receptor inhibitors by the** 92 **yeast two-hybrid assay**

93 According to the former report (26), we synthesized a series of 1,2,3-triazole ureas by mixing
94 unsubstituted 1,2,3-triazole and five different carbamoyl chlorides with *N,N*-dimethyl-4-
95 aminopyridine. This synthetic procedure yielded mixtures of N1- and N2-carbamoylated
96 regioisomers. Most of these mixtures were separated by silica gel chromatography, and we
97 obtained eight different 1,2,3-triazole urea congeners (Fig. 1A, **1–8**).

98 To test whether these compounds are potent inhibitors of D14, we used the yeast two-
99 hybrid (Y2H) assay to monitor SL-dependent D14–D53 interaction. Growth of AH109 yeast
100 transformed with pGBK-D14 and pGAD-D53 in the SD+His Ade media were not inhibited by
101 any KK compounds tested at the concentration of 50 μ M showing that all KK compounds are not
102 toxic for yeast growth at this concentration (data not shown). All tested compounds inhibited the
103 D14–D53 interaction induced by GR24, a synthetic SL mimic, although the inhibitory effect of
104 KK003 (**3**, **4**) was weaker than that of the other congeners (Fig. 1B).

105 To obtain highly specific and potent D14 inhibitors, we then diversified the structures of
106 1,2,3-triazole urea compounds. The 1,2,3-triazole urea scaffold consists of two major sites for
107 diversification: the carbamoyl group and the 1,2,3-triazole leaving group. Adibekian et al. showed
108 that 4-substitution of the 1,2,3-triazole group of 1,2,3-triazole ureas enhanced their potency and
109 selectivity as serine hydrolase inhibitors (26). Therefore, we introduced various substituents onto
110 the 4-position of the 1,2,3-triazole group of KK007, which clearly inhibited the D14–D53 and
111 D14–SLR1 interactions induced by GR24 (fig. S1A, **9–15**). We tested these in the Y2H assay, but
112 none of these compounds inhibited the D14–D53 and D14–SLR1 interactions induced by GR24
113 (fig. S1B), indicating that the unsubstituted 1,2,3-triazole is essential for the inhibition of D14
114 activity.

Next, we diversified our collection of D14 inhibitor candidates by converting carbamoyl groups. We synthesized 1,2,3-triazole urea compounds by modifying the morpholine structure of KK004 (fig S1C, **16–25**), and the pyrrolidine structure of KK007 (Fig. 1A, **26–27**). All of these were tested in the Y2H assay (Fig. 1D and fig. S1D). As a result, we selected KK002-N1, KK004-N1, KK007-N1, KK052, KK053, KK055, KK075, and KK094 for further assays.

Inhibitory effects of candidate compounds on the suppression of rice tillering by GR24

To confirm whether the selected compounds are good SL-receptor inhibitor candidates, we used *in planta* assays. In hydroponically grown rice seedlings, the first and second tiller buds of SL-deficient mutants, such as *d10* and *d17*, grow out, whereas those of wild-type plants remain dormant (27). Treatment of these mutants with SLs restores the dormant phenotype of the first and second tiller buds. Therefore, we performed a rice tillering assay to test whether 1,2,3-triazole ureas attenuate the tiller-inhibiting effects of SLs. When 10 μ M of 1,2,3-triazole ureas and 0.1 μ M of GR24 were applied together to hydroponically grown *d17-1* rice, several 1,2,3-triazole ureas restored the growth of the first and second tiller bud that had been suppressed by GR24 (Fig. 1C). KK052 (**16**), KK053 (**17**), and KK094 (**26**) significantly restored the tiller bud outgrowth of rice (Fig. 1C). Among them, the effect of KK094 treatment was prominent. KK094 did not inhibit the growth of rice, while KK052 did (fig. S2). We then substituted the 1,2,3-triazole group of KK094 to 1,3-imidazole group to yield KK122 and tested it using the Y2H assay and the rice tillering assay. KK122 did not inhibit the GR24-induced D14–D53 and D14–SLR1 interactions, or the tillering inhibition produced by GR24 (fig. S3). These data indicate that the 1,2,3-triazole group is indispensable for the inhibition of D14 function. Next, we generated various KK094 derivatives by modifying the indoliny structure of KK094 (fig. S4, **29–41**); however, none of these was a

stronger inhibitor than KK094. Thus, we selected KK094 as the most potent SL-receptor inhibitor candidate, and KK122 as a negative control compound of KK094.

We then treated hydroponically grown seedlings of wild-type rice (Nipponbare) with 10 μ M KK094 and found that it significantly promoted the outgrowth of the first and second tiller buds (Fig. 1D), and this outgrowth promotion was concentration-dependent (Fig. 1E). The KK094 treatment decreased plant height. A semi-dwarf phenotype is a characteristic of SL-deficient mutants. These features resulting from KK094 treatment support the hypothesis that this compound acts as an SL-signaling inhibitor in rice. Furthermore, we investigated whether KK094 can inhibit the germination of parasitic plants and found that it could inhibit GR24-induced seed germination of *Striga hermonthica* (fig. S5A).

KK094 inhibits SL-hydrolysis

Because KK094 was originally designed to inhibit the SL-hydrolytic activity of D14 by direct binding to its catalytic center, we tested whether KK094 inhibits D14-induced SL-hydrolysis. When 0.2 μ M of GR24 was incubated with the purified recombinant D14 for 30 min, and GR24 and the reaction product, ABC-OH, were extracted and detected by LC-MS, a decrease in the amount of GR24, and an increase in the amount of ABC-OH were observed (fig. S6A–C). We next conducted the SL-hydrolysis assay at various concentrations of KK094. As a result, KK094 efficiently inhibited the decrease in the amount of GR24, and the increase in the amount of ABC-OH produced by D14, and these inhibitory effects were concentration-dependent (Fig. 2A). KK094 itself was also hydrolyzed by D14 (fig. S6D), indicating that the hydrolyzed product may bind to the catalytic pocket of D14 and impede entry of SL into the pocket.

Yoshimulactone Green (YLG) is a fluorogenic SL-agonist which suppresses the more axillary branching phenotype of the *Arabidopsis max4* mutant and stimulates the seed germination of *Striga* (28). YLG can be efficiently hydrolyzed by AtD14 and *Striga hermontica*

SL receptors (ShHTLs). YLG-hydrolysis by SL receptors generates the fluorescent product. First, we observed that recombinant D14 protein hydrolyzed YLG to yield green fluorescence, which over time showed a Michaelis constant (K_m^{YLG}) value at 1.84 μ M (Fig. 2C). This reaction was competitively inhibited by GR24, and the median inhibitory concentration (IC_{50}) was 5.8 μ M (Fig. 2B). Then we investigated whether KK094 competes with YLG in its hydrolysis by D14. KK094 is a mixture of regioisomers, KK094-N1 and KK094-N2, which we separated using silica gel chromatography. Both the N1 and N2 isomers of KK094 inhibited YLG hydrolysis by D14, with IC_{50} values of 1.8 and 7.9 μ M, respectively (Fig. 2B). KK122 did not inhibit YLG hydrolysis (Fig. 2B), indicating that the 1,2,3-triazole moiety is essential for the inhibition of YLG hydrolysis and that the inhibition of YLG hydrolysis is required for the inhibition of SL-signaling. The K_m^{YLG} value was unchanged in the presence of KK094-N1 at a concentration of 0.3 μ M. However, KK094-N1 treatment at a concentration of 0.3 μ M decreased the V_{max}^{YLG} to nearly half the level observed following sham treatment (Fig. 2C), and the increase of KK094-N1-pretreatment time potentiated the inhibitory effect (Fig. 2D). These data strongly support the hypothesis that KK094 is a covalent inhibitor of D14.

We also assessed the inhibitory effect of KK094 on SL-hydrolysis activity of *Striga* SL-receptors using YLG. *S. hermonthica* receives SL by the ShHTL protein, of which there are 11 subtypes, upon SL-induced seed germination. Among them, the ShHTL7 subtype is reported to be the most sensitive SL receptor (29) mediating SL-induced seed germination, therefore, we used the ShHTL7 protein in the YLG assay. The IC_{50} of KK094 was more than 20 μ M, while that of GR24 was 0.15 μ M (fig. S5B).

Next we monitored the interaction between KK094 and D14 using differential scanning fluorimetry (DSF). DSF revealed a shift in the D14 melting temperature in the presence of KK094, indicating that KK094 interacts with D14 and changes its stability; however, with KK094 treatment, this shift was not observed in D14^{H297A} in which the catalytic residue is mutated (19)

(Fig. 2E). The 8 °C increase in D14 melting temperature suggests that the stabilization of D14 and the potent inhibitory effect of KK094 are correlated.

KK094 inhibits SL-induced formation of the D14–D53 complex *in vitro*

We performed *in-vitro* pull-down assays (Fig. 3A) using a two-step treatment of D14 with test compounds; D14 was treated with the first compound, and then washed and incubated with D53 in the presence of the second compound. The single treatment with KK094 did not induce the D14–D53 interaction when it was added in either step. Meanwhile, the single treatment with GR24 did not induce the interaction when it was added in the first step, but it did only when added in the second step, indicating that a hydrolyzed product of GR24 could be washed away from the catalytic pocket. However, when D14 was treated with KK094 (first step) and GR24 (second step), the interaction was not detected, indicating that a hydrolyzed product of KK094 stayed in the pocket and inhibited GR24 hydrolysis, and the hydrolyzed product was not washed away in the washing step. These results strongly support a mechanism of covalent inhibition by KK094. A concurrent treatment with KK094 and GR24 weakened the interaction between D14 and D53 as compared with GR24 alone.

Crystal structure of the D14–KK094 complex

To determine the binding mode of KK094 in the catalytic pocket of D14, we solved the crystal structure of the D14–KK094 complex at 1.45 Å resolution (table S1, Fig. 3B). The asymmetric unit contains two molecules of D14 with almost identical structures; the root mean square deviation (r.m.s.d.) was 0.37 Å for the main chain C α atoms. As reported previously, D14 consisted of a core domain, also known as α/β hydrolase domain (30), and a cap domain composed of four helices forming two antiparallel V shapes (Fig. 3B). A catalytic pocket was formed between the two domains, and the catalytic residue S147 is located at the bottom of the

214 pocket and is aligned with H297 and D268 to form the catalytic triad. The electron density map of
 215 the D14–KK094 complex clearly showed the existence of a covalently bound KK094-derived
 216 carbamoyl moiety (KK094CM), which is assumed to be a hydrolyzed product of KK094, to the
 217 hydroxyl group of S147 (Fig. 3C). In the complex structure of D14–KK094CM, the covalently
 218 bound KK094CM was embedded completely in the cavity and was surrounded by V148, V240,
 219 C241, V244, S270 and H297, and several aromatic residues, such as F78, F176 and F245 (Fig.
 220 3D). These residues made favorable hydrophobic and/or van der Waals interactions with
 221 KK094CM. In addition, the carbonyl group of KK094CM formed a hydrogen bond network with
 222 F78, V148, and H297 including two water molecules (Fig. 3D). In this complex structure,
 223 KK094CM is deduced to deprive canonical substrates of opportunities to invade and be
 224 hydrolyzed by occupying the active site in the catalytic pocket of D14. The D14–KK094CM
 225 complex and the apo-D14 (PDB ID 3VXK) (19) have almost identical structures (r.m.s.d. 0.16 Å),
 226 but some minor structural differences occurred in the catalytic pocket (fig. S7A). The side chain
 227 of S147 flipped toward KK094CM due to the covalent modification. In addition, upon KK094CM
 228 binding, the side chain of F245 moved 1 Å away from the KK094CM, creating a space to
 229 accommodate KK094 binding (fig. S7B). This change is consistent with previous structural
 230 studies regarding the flexibility of the Phe residue located in this conserved site (19, 31–33).

232 **Hydrolyzed product of KK094 covalently binds to D14**

233 We further confirmed whether KK094 covalently binds to D14 using Matrix Assisted Laser
 234 Desorption/Ionization-Time of Flight (MALDI-TOF) mass spectrometry and Liquid
 235 Chromatography-Tandem Mass Spectrometry (LC-MS/MS) analysis. D14 was incubated with or
 236 without KK094 in 1 mL of PBS at 25 °C for 35 min, and 100 µL of the reaction solution was
 237 analyzed using MALDI-TOF mass spectrometry (Fig. 4A). The molecular weight of D14
 238 incubated without KK094 was determined to be 29283.3 (-KK094; Fig. 4A), which was almost

the same as that deduced from the amino acid sequence of the purified D14 protein (molecular weight: 29285.8). The molecular weight of D14 incubated with KK094 was determined to be 29429.7 (+KK094; Fig. 4A). The 146.4 Da difference was thought to represent the covalently bound KK094CM (Fig. 4A), which adds 145 Da.

The remaining reaction mixtures were then dialyzed and digested with trypsin, and generated peptides were analyzed using MALDI-TOF mass spectrometry (fig. S8A). The amino acid sequences of the digested peptides were deduced based on their molecular masses (table S2). The fragment corresponding to the peptide 141–159 ($^{141}\text{CAFVGHSVSAMIGILASIR}^{159}$; m/z 1932.446) was not detected when D14 was incubated with KK094 (fig. S8B). On the contrary, the peptide fragment with molecular mass of 2077.454 was detected when D14 was incubated with KK094, although it was not detected when D14 was incubated without KK094. This fragment corresponds to the peptide 141–159 with covalently bound KK094CM (fig. S8B).

To confirm the carbamylation site in peptide 141–159, we conducted LC-MS/MS analysis (Fig. 4B). When trypsin-digested fragments of D14 incubated with KK094 were analyzed, the addition of 145 Da was observed in the y13 and y15 ions but not in the y4–y12 ions (Fig. 4B; table S3), demonstrating that carbamylation occurred at S147.

Some KK052-derived 1,2,3-triazole ureas show agonist activity in the formation of the D14–D53 complex

As described above, KK052 acted as an SL-antagonist in Y2H and rice tillering assays (fig. S1C and D), but its inhibition seemed weaker than that of KK094 (Fig. 1A). Two KK052-derivatives, KK053 and KK055, showed antagonism both in the Y2H and rice tillering assays (fig. S1C, D and Fig. 1C). Unexpectedly, some KK052-derivatives, KK054, KK067, KK070, and KK073 showed agonism in the formation of the D14–D53/D14–SLR1 complex in the Y2H assay (fig. S9

and Fig. 5A). Interestingly, these agonists had polar groups. Among them, the agonistic effect of KK073 was prominent (Fig. 5A). Thus, we further analyzed the activity of KK073.

KK052 inhibits the SL-induced formation of the D14–D53 complex and KK073-induced D14–D53 complex formation *in vitro*

We further conducted *in vitro* pull-down assays using GR24, KK052, and KK073 (Fig. 5B). Like the pull-down assay using KK094, we also used a two-step treatment of D14 with this group of compounds. A single treatment with KK052 did not induce the D14–D53 interaction when it was added in either step. As observed for the KK094 treatment (Fig. 3A), when D14 was treated with KK052 (first step) and then GR24 (second step), the D14–D53 interaction was not detected, indicating that a hydrolyzed product of KK052 (KK052CM) stayed in the pocket and inhibited the action of GR24. Meanwhile, the interaction between D14 and D53 was induced when KK073 was added in either step (Fig. 5B). When a combination of KK073 and KK052 was added, the interaction was induced only when KK073 was added in the first step. These results indicate that a hydrolyzed product of KK073, KK073CM, is not washed away from the catalytic pocket and promotes the formation of the D14–D53 complex by a mode of agonistic action different from GR24.

The hydrolyzed products of KK052 and KK073 covalently bind to D14

To determine whether KK052 and KK073 also covalently bind to D14, we solved the crystal structures of the D14–KK052 and the D14–KK073 complex at 1.49 Å and 1.53 Å resolution, respectively (table S1 and Fig. 6A). The electron density map of the D14–KK052 and D14–KK073 complex clearly showed the existence of a covalently bound KK052CM or KK073CM, respectively, to the hydroxyl group of S147 (Fig. 6B). In these complex structures, the covalently bound KK052CM was embedded completely within the cavity, whereas the trifluoromethyl group

of KK073CM partially protruded out of the pocket. Both binding sites consisted of V148, I191, V194, C241, V244, S270 and H297, and several aromatic residues, such as F78, F176, F186, W205, Y209, and F245 (Fig. 6C). These residues made favorable hydrophobic and/or van der Waals interactions with KK052CM/KK073CM. In addition, the carbonyl group of KK052CM/KK073CM formed a strong hydrogen bond network with F78, V148, Y209, S270 and H297 mediated by three water molecules (Fig. 6C). Like KK094CM, KK052CM/KK073CM appears to deprive canonical substrates of opportunities to invade and react by occupying the active site. Interestingly, when the structure of the D14–KK073CM complex was compared to that of the D14–D-OH complex (PDB ID 3WIO) (19), the trifluoromethyl group of KK073 resided at nearly the same site as the D-OH in the D14–D-OH complex (Fig. 6D). Both the trifluoromethyl group of KK073 and D-OH were located at the aperture of the binding pocket of D14 and surrounded by aromatic residues, such as F186, W205, Y209, and F245. In addition, the trifluoromethyl group of KK073 protruded from the binding pocket and was directly exposed to the solvent; fluorine atoms faced on the surface of D14, generating a polar region in the overall hydrophobic surface of D14 (Fig. 6E). To confirm this hypothesis, we tested KK182, in which a methylene group was inserted between the benzene ring and the piperazine ring, and the distance between the trifluoromethyl group and the carbonyl group is elongated. When KK182 was tested in the Y2H assay, KK182 antagonized the formation of D14–D53 (fig. S9B). These data support the hypothesis that the position of the trifluoromethyl group is critical for the agonistic effect on the formation of the D14–D53/D14–SLR1 complex.

Both KK052 and KK073 antagonized the inhibition of rice tillering produced by SL

From the above results, we assumed that KK052 acts as an SL-antagonist, and KK073 acts as an SL-agonist *in planta*. To confirm this assumption, we tested KK052 and KK073 in the rice tillering assay. Unexpectedly, both KK052 and KK073 showed inhibitory effects on the tillering

inhibition by GR24, and KK073 did not act as an SL-agonist (fig. S10A). Generally, SL-agonists decrease the D14 melting temperature (12, 20), which is required for the conformational change in the interaction with D3/MAX2. However, KK073 as well as KK094 (Fig. 2E), increased the melting temperature (fig. S10B), indicating that KK073 interacts with D14 and changes the stability of D14, and this shift was not observed in D14^{H297A}. Consistent with this, we found that KK073 could not induce the interaction of D14 with the D3–OSK1 complex in the yeast three-hybrid assay (Fig. 5A).

Discussion

The irreversible mode of inhibition of covalent inhibitors has potential benefits, such as high potency extended duration of action as compared with that of the reversible mode of inhibition of noncovalent inhibitors. In this study, we reported the development of 1,2,3-triazole ureas with inhibitory effects on SL activity. Among them, KK094 was the most potent SL-inhibitor. KK094 restored the growth of the first and second tiller bud of hydroponically grown *d17-1* rice that has been suppressed by GR24 (Fig. 1C). KK094 also showed an inhibitory effect on the regulation of tiller bud growth by SLs and the treatment of wild-type rice with KK094 stimulated the growth of tiller buds (Fig. 1D, E). KK094 efficiently inhibited the hydrolysis of GR24 by D14, and this inhibition did not change the K_m value, but markedly lowered the V_{max} value of the hydrolysis reaction (Fig. 2). Pull down analyses showed that KK094 prevents the formation of D14–D53 complex *in vitro* (Fig. 3). KK094 could be hydrolyzed by D14 (fig. S6D), and the hydrolyzed product (KK094CM) covalently binds to the hydroxyl group of a Ser residue in the catalytic triad of D14, as indicated by the crystal structure analysis (Fig. 3B-D) and the LC-MS/MS analysis (Fig. 4). Based on these data, we conclude that KK094 is a potent covalent inhibitor for the strigolactone receptor.

Recently, Xiang et al. reported that β -lactones covalently bind to Arabidopsis D14 and inhibit the activity of AtD14 as an SL receptor (7). Here, we used 1,2,3-triazole ureas because they are easily synthesized using a simple scheme. This is a great advantage of 1,2,3-triazole ureas, and we synthesized a wide variety of 1,2,3-triazole urea compounds and tested them both using *in planta* and *in-vitro* assays and found some compounds with a spectrum of activities. Among them, we are interested in the compounds which seemed to act as agonists for the formation of D14–D53/D14–SLR1 complex in Y2H assays.

In our Y2H assays, KK052 inhibited SL-induced formation of the D14–D53 complex, while KK073 induced formation of the D14–D53 complex. This agonistic effect of KK073 was also observed in the pull-down assay. The difference between KK052 and KK073 is the existence of a trifluoromethyl group on the benzene ring. The opposite activity of KK052 and KK073 resulted from the slight difference which provides clues to a deeper insight into the mechanism of the formation of the D14–D53 complex.

In the pull-down assay, KK094 inhibited SL-induced formation of the D14–D53 complex by forming a covalent bond with the catalytic S147 residue. This result indicates that the complex formation requires SL binding into the catalytic pocket followed by its hydrolysis. The previous report showed that the hydrolyzed product of SL covalently bound to the catalytic site of D14 (20,21). They showed that this binding evoked dramatic changes in the overall structure of D14 and induced D14–MAX2 complex formation (21). In contrast, SL-induced formation of the D14–D53 complex could not be detected following a washing step of D14 in complex with SL before the incubation with D53, suggesting that the hydrolyzed product of SL binds non-covalently to D14 and induces the formation of the D14–D53 complex. In our previous report, we observed the non-covalently bound D-OH in the entrance of the ligand binding pocket of D14. It is possible that this D-OH induces the formation of the D14–D53 complex in a way different from that in the formation of D14–MAX2 complex.

Unlike GR24, KK073 could induce the formation of the D14–D53 complex even when it was added before the washing step in the pull-down assay. Furthermore, we observed covalent binding of KK073CM to the S147 residue of D14 using X-ray crystallography. Interestingly, the trifluoromethyl group of KK073CM in the D14–KK073CM crystal resided at almost the same site as the D-OH in the D14–D-OH crystal (Fig. 8). Both the trifluoromethyl group of KK073 and D-OH were located at the aperture of the D14 binding pocket. No major change of the overall structure of the complex was observed in both the D14–D-OH (19) and D14–KK073CM complexes (fig. S7).

KK052 could not induce the D14–D53 interaction, while KK073 could function as an agonist for the formation of the D14–D53 complex. The position of KK073CM in the binding pocket of D14 was almost the same as that of KK052CM, and the only difference is the trifluoromethyl group on the benzene ring of KK073CM. These data strongly indicate that the formation of the D14–D53 complex requires an additional polar region (e.g., D-OH, trifluoromethyl group) at the entrance of the binding pocket of D14. In addition, there are no structural differences in D14 between the KK073CM- and KK052CM-bound forms, suggesting that the formation of the D14–D53 complex does not require the structural changes that are observed in the D14–D3/MAX2 complex. Indeed, we found that KK1073 could not induce the formation of the D14–D3/MAX2 complex in the yeast three-hybrid assay (Fig. 5C). Furthermore, KK073 increased the D14 melting temperature in the DSF assay (fig. S10B) as well as KK094, while SL-agonists generally decrease the D14 melting temperature (12,20). In general, the decrease of the melting temperature reflects the destabilization of protein that correlates with the conformational change, which is consistent with the dynamic structural changes of D14 in the complex with D3/MAX2 with SL-agonists. In the D14–D3/MAX2 complex, the reposition of the catalytic triad accompanying the formation of CLIM may induce the destabilization of D14 (21). On the other hand, covalently bound KK094CM/KK073CM interacts with many residues

composing the pocket and is likely to decrease their flexibility, resulting in the stabilization of D14. These data also support a model of the static formation of the D14–D53 complex.

These speculations raise the question of how D14 interacts with both D53 and D3/MAX2 by different means. We do not have any direct evidence to answer this question. Investigation of the structure of the complex containing D14, D53 and D3/MAX2 might provide insights regarding this question.

Although KK094 strongly inhibited the SL activity in the suppression of the outgrowth of branching buds, the inhibitory effect of KK094 on the SL-induced germination of *Striga* seeds was relatively weak (fig S5). A greater KK094/GR24 ratio was required to inhibit *Striga* seed germination than to inhibit the tillering suppression activity of GR24. This weak inhibition of *Striga* seed germination by KK094 is consistent with the difference in IC₅₀ values for the hydrolysis activity of ShHTL7 and D14. However, modification of KK094 might improve its inhibitory effect on the functions of *Striga* HTL proteins. Thus, KK094 and its derivatives have the potential to regulate plant growth and seed germination of parasitic plants both in laboratories and in fields, and KK052/KK073 and their derivatives are expected to be powerful tools to elucidate the complicated mechanisms underlying SL-perception and signal transduction.

Materials and Methods

Plant materials and the rice tillering assay. An SL-deficient rice mutant, *d10-2*, of the Japonica-type cultivar (*Oryza sativa* L. cv. Nipponbare) and a *d17-1* rice mutant of the Japonica-type cultivar (*Oryza sativa* L. cv. Shiokari) were used in this assay. The rice seeds were sterilized in a 2.5% sodium hypochlorite solution containing 0.02% Tween 20 for 20 min. The seeds were washed five times with sterilized water and then incubated in tubes filled with water at 25 °C in the dark for 2 days. The germinated seeds were planted in a hydroponic culture medium (34) solidified with 0.6% agar and cultivated at 25 °C under fluorescent light (70–100 μmol⁻² sec⁻¹)

with a 16-hr light/8-hr dark photoperiod for 7 days. Each seedling was transplanted to a glass vial filled with 12 mL of sterilized hydroponic culture solution with or without an experimental compound and grown under the same conditions for 7 days.

Yeast two-hybrid (Y2H) and yeast three-hybrid (Y3H) assays. The Matchmaker Two-Hybrid System (Takara Bio, Otsu, Japan) was used for the Y2H assay. We used pGBK-D14 (19) as the bait and pGAD-SLR1 (19) or pGAD-D53 (6) as the prey. The *Saccharomyces cerevisiae* AH109 strain was transformed with the bait and prey plasmids and grown in liquid medium for 2 days. The plate assays (synthetically defined medium without histidine and adenine) were performed according to the manufacturer's protocol, except that the plate medium contained various combinations of SLs and test compounds. For the Y3H assay, the yeast strains AH109 and the plasmids pGADT7 were also used and pBridge were obtained from Takara Bio Inc. pBridge-BD:D14-M:OSK1 was constructed by fusing D14 cDNA with the GAL4-BD domain and inserting OSK1 cDNA (Os11g0456300) into the site downstream of pMET25. pGAD-D3 was constructed by fusing D3 cDNA (AK065478) with the GAL-AD domain. AH109 was transformed with the pBridge-BD:D14-M:OSK1 and pGAD-D3 or pGADT7 selected on SD media lacking L-tryptophan (SD-Trp Leu Met). For the assay, the transformants were incubated on SD-Trp, Leu and Met media that lacked Ade and His (SD-His Ade Met).

***Striga* germination assay.** *Striga* seed germination assay was performed as described previously (35). Seeds of *Striga hermonthica* harvested in Sudan were kindly provided by Professor A.E. Babiker (Sudan University of Science and Technology) and imported with the permission of the Minister of Agriculture, Forestry and Fisheries of Japan. Seeds of *S. hermonthica* were sterilized with a 1% sodium hypochlorite solution containing 0.01% Tween 20 for 5 min and washed five times with sterilized water. The seeds were then added to a 0.1% agar solution and dropped onto

small, round, glass-fiber filters. Filters containing the seeds were arranged on a filter paper (70 mm diameter) in a Petri dish, and 1400 μ L of sterilized water including the appropriate chemical was added to the dish. The dishes were incubated at 30 °C in the dark for 4 days. The small filters containing the seeds were transferred to a 96-well plate, and 10 μ L of sterilized water or water including the appropriate chemical was added to each well. After incubation for 2 days under the same conditions, the number of germinated seeds was counted.

Protein preparation. D14 was expressed in *E. coli* and purified as described previously (2). Briefly, D14 (residues 54–318) from rice was expressed with the pET-49b expression vector (Merck-Millipore) in *E. coli* Rosetta (DE3) cells (Merck-Millipore). The cells were harvested, resuspended in extraction buffer (20 mM Tris-HCl (pH 8.5), 500 mM NaCl, 10% glycerol and 3 mM dithiothreitol (DTT)), and disrupted by sonication. The soluble fraction separated by centrifugation was purified using Glutathione Sepharose 4B resin (GE Healthcare). For crystallization, on-column cleavage was performed by adding HRV3C protease, and the eluted D14 was further purified using a Resource S column (GE Healthcare). The purified D14 was concentrated to 6.0 mg mL⁻¹ in buffer containing 20 mM MES-NaOH (pH 6.5), 300 mM NaCl, 10% glycerol, and 5 mM DTT. For pull-down assays, GST fusion D14 was eluted with elution buffer (20 mM Tris-HCl (pH 7.8), 500 mM NaCl, 100 mM reduced glutathione and 5 mM DTT. After the eluted product was concentrated and diluted 25-fold in elution buffer lacking NaCl and reduced glutathione, GST-D14 was further purified using a Resource S column. The purified GST-D14 was concentrated to 5 μ M in buffer containing 20 mM Tris-HCl (pH 7.8), 100 mM NaCl and 5 mM DTT. The *D53* open reading frame fragment was amplified by PCR using total complementary DNA from rice seedlings. For expression in *E. coli*, the PCR product was cloned into the expression vector pGEX-6P-3 (GE Healthcare), and subsequently transformed into *E. coli* Rosetta (DE3) cells. The cells were grown in Luria-Bertani broth at 37 °C to an OD₆₀₀ of ~0.6 and

induced with 0.5 mM isopropyl- β -D-thiogalactopyranoside at 15 °C for 32 h. The cells were harvested, resuspended in extraction buffer (20 mM Tris-HCl (pH 8.5), 500 mM NaCl and 5 mM DTT), and disrupted by sonication. The soluble fraction separated by centrifugation was purified using Glutathione Sepharose 4B resin. On-column cleavage was performed by adding HRV3C protease, and the eluted D53 was further purified using a Mono Q column and Superdex 200 columns (GE Healthcare). The purified D53 was concentrated to 5 μ M in buffer containing 20 mM Tris-HCl (pH 7.8), 100 mM NaCl and 5 mM DTT for pull-down assays.

Hydrolysis assay. GR24 and KK094 pre-incubated at 30 °C for 10 min and incubated further at 30 °C for 20 min after the addition of 0.33 μ M of D14. After adding 5 nmol of CPMF (5-(4-chlorophenoxy)-3-methylfuran-2(5H)-one) (36) as an internal standard, reaction solutions were extracted with ethyl acetate three times. Ethyl acetate layers were combined, dried in vacuo, and then dissolved with 50 μ L methanol. Each sample was injected at a volume of 5 μ L into the reverse-phase HPLC column (CAPCELL CORE C18, 2.1 μ m $\times$ 100 mm, Shiseido, Tokyo, Japan), coupled to the ESI-MS system (LC-2030C/3D, Shimadzu, Kyoto, Japan). The analytes were eluted with a linear gradient of 40–90% buffer B (methanol with 0.1% (v/v) formic acid) in buffer A (MilliQ water with 0.1% (v/v) formic acid) within 9 min, keeping the final condition for 6 min. The column was operated at 40 °C with a flow rate of 0.2 mL min⁻¹. Quantities of GR24 or ABC-OH were monitored at m/z = 299.10 or 202.06, respectively, and normalized by the amount of CPMF monitored at m/z = 224.02. The amount of GR24 incubated without D14 was set to 1. Error bars indicate SE of six seedlings. Student's *t*-test was used to determine the significance of differences (**p*<0.05, ***p*<0.01).

Yoshimulactone G *in vitro* analysis. In the hydrolysis assay, 0.3 μ M of YLG was reacted with 0.33 μ M of recombinant proteins (D14 or ShKAI2d6/ShHTL7) in a reaction buffer (100 mM PBS

489 buffer, pH 7.3) with 0.1% dimethyl sulfoxide (DMSO) at a 300 μ L volume on a 96-well black
 490 plate (Thermo). The fluorescent intensity was measured by ThermoFisher at the excitation by 485
 491 nm, and detected at a wavelength of 535 nm. The enzymatic reaction was carried out in a 30 °C
 492 incubator for 15 min. IC₅₀ values were calculated using the website:
 493 <http://www.ic50.tk/index.html>.

495 **Differential Scanning Fluorometry.** DSF experiments were performed using CFX Connect
 496 Real-Time PCR Detection System (Bio-Rad, CA). Sypro Orange was used as a reporter dye.
 497 After pre-incubation of the reaction mixtures for 5 min and 10 s at 20 °C, reaction mixtures were
 498 denatured using a linear 20 °C to 95 °C gradient at a rate of 0.5 °C per 10 s in the absence of light.
 499 Each reaction was carried out at 20- μ L scale in TN buffer (10 mM Tris-HCl, pH=8.0, 200mM
 500 NaCl) containing 5 μ M protein, 0.01 μ L Sypro Orange, and each concentration of experimental
 501 compounds (final DMSO concentration was 10%). The experiments were repeated twice.

502
 503 **Pull-down assays.** Pull-down assays of GST-D14 and D53 were performed using a two-step
 504 treatment with experimental compounds. The purified GST-D14 (5 μ M) was incubated at 4 °C for
 505 30 min with Glutathione Sepharose 4B resin, and then washed three times. The glutathione
 506 agarose-bound GST-D14 was incubated with or without 50 μ M of each experimental compound
 507 at room temperature for 2 h (first step) and then washed three times. The resin-bound GST-D14
 508 was incubated with D53 (5 μ M) with or without 50 μ M of each experimental compound at room
 509 temperature for 2 h (second step), then washed three times. Eluted proteins were separated using
 510 SDS-PAGE electrophoresis (10% gel) and detected using CBB staining.

511
 512 **Crystallization and structure determination.** 6.0 mg/ml of D14 protein and 10 mM
 513 KK094/KK052/KK073 were mixed together and subjected to crystallization by the sitting drop

vapor diffusion method. Crystals of the D14–KK094CM complex were obtained at 20 °C using a reservoir solution containing 100 mM MES (pH 6.5) and 13% PEG20000. Crystals of the D14–KK052CM complex were obtained at 20 °C using a reservoir solution containing 100 mM HEPES (pH 7.5) and 13% PEG20000. Crystals of the D14–KK073CM complex were obtained at 20 °C using a reservoir solution containing 100 mM MES (pH 6.5) and 11% PEG 20000. All crystals were soaked in the cryo-protectant solution containing 25% (v/v) ethylene glycol and then flash-cooled with a nitrogen-gas stream at 100 K. All X-ray diffraction data were collected on the BL-1A beamline at the Photon Factory (Tsukuba, Japan) and processed using the XDS package (37). Molecular replacement was performed using Phaser (38) in PHENIX (39) with the apo-D14 structure (PDB ID 3VXK) (19) as the initial model. Coot (40) was used to manually fit the protein models, and the structure was refined with PHENIX. The geometry of the final model was analyzed using RAMPAGE (41), and superposition and r.m.s.d. of the structures were calculated using the CCP4 program LSQKAB (42). All structure Figures were prepared using PyMOL (43,44). X-ray data and refinement statistics are given in table S1. Coordinates of the X-ray structures of the D14–KK094CM complex, the D14–KK052CM complex, and the D14–KK073CM complex have been deposited in the Protein Data Bank, under accession codes 5ZHR, 5ZHS and 5ZHT, respectively.

Mass Spectrometry. For the identification of the KK094CM binding site, the reaction mixtures (ca. 1.6 mg mL⁻¹) of D14 with or without KK094 were dialyzed against 50 mM of NH₄HCO₃ solution. Aliquots of the dialyzed samples were analyzed using MALDI-TOF MS on an ultrafleXtreme TOF/TOF Mass Spectrometer (Bruker Daltonics, Bremen, Germany) in a linear mode using sinapinic acid as a matrix. After confirmation of KK094 binding to the protein using MALDI-TOF MS, the dialyzed samples were digested with trypsin (TPCK treated, Worthington Biochemical Co.) overnight at 37 °C. Aliquots of the digestion mixture were also applied to

MALDI-TOF MS in reflector mode using α -cyano-4-hydroxycinnamic acid as a matrix. For binding site determination, the digests were further analyzed by nano-liquid chromatography-tandem mass spectrometry using a Q Exactive mass spectrometer (Thermo Fisher Scientific). The peptide mixtures (2 μ L) were separated using a nano ESI spray column (75 μ m [ID] $\times$ 100 mm [L], NTCC analytical column C18, 3 μ m, Nikkyo Technos, Tokyo, Japan) with a linear gradient of 0–35% buffer B (acetonitrile with 0.1% (v/v) formic acid) in buffer A (MilliQ water with 0.1% (v/v) formic acid) at a flow rate of 300 nL min⁻¹ over 10 min (EAST-nLC 1000; Thermo Fisher Scientific). The mass spectrometer was operated in the positive-ion mode, and the MS and MS/MS spectra were acquired using a data-dependent TOP10 method. The MS/MS spectra were drawn using the Qual Browser, Thermo Xcalibur 3.1.66.10.

Preparation of KK compounds. A description is available in the **Supplementary Notes**.

References and Notes

1. M. T. Waters, C. Gutjahr, T. Bennett, D. C. Nelson, Strigolactone Signaling and Evolution. *Annu Rev Plant Biol* **68**, 291–322 (2017).
2. H. Nakamura, T. Asami, Target sites for chemical regulation of strigolactone signaling. *Front Plant Sci* **5**, 623 (2014).
3. S. Lumba, M. Bunsick, P. McCourt, Chemical genetics and strigolactone perception. *F1000Res* **6**, 975 (2017).
4. H. Samejima, A. G. Babiker, H. Takikawa, M. Sasaki, Y. Sugimoto, Practicality of the suicidal germination approach for controlling *Striga hermonthica*. *Pest Manag Sci* **72**, 2035–2042 (2016).
5. D. Holbrook-Smith, S. Toh, Y. Tsuchiya, P. McCourt, Small-molecule antagonists of germination of the parasitic plant *Striga hermonthica*. *Nat Chem Biol* **12**, 724–729 (2016).
6. O. Mashita, H. Koishihara, K. Fukui, H. Nakamura, T. Asami, Discovery and identification of 2-methoxy-1-naphthaldehyde as a novel strigolactone-signaling inhibitor. *Journal of Pesticide Science* **41**, 71–78 (2016).
7. H. Xiang, R. Yao, T. Quan, F. Wang, L. Chen, X. Du, W. Zhang, H. Deng, D. Xie, T. Luo, Simple β -lactones are potent irreversible antagonists for strigolactone receptors. *Cell Res* **27**, 1525–1528 (2017).
8. M. Yoshimura, A. Sato, K. Kuwata, Y. Inukai, T. Kinoshita, K. Itami, Y. Tsuchiya, S. Hagihara, Discovery of shoot branching regulator targeting strigolactone receptor DWARF14. *ACS Central Science* **4**, 230–234 (2018).

9. C. Hamiaux, R. S. M. Drummond, Z. Luo, H. W. Lee, P. Sharma, B. J. Janssen, N. B. Perry, W. A. Denny, K. C. Snowden, Inhibition of strigolactone receptors by. *J Biol Chem* **293**, 6530–6543 (2018).
10. S. Lumba, D. Holbrook-Smith, P. McCourt, The perception of strigolactones in vascular plants. *Nat Chem Biol* **13**, 599–606 (2017).
11. T. Arite, H. Iwata, K. Ohshima, M. Maekawa, M. Nakajima, M. Kojima, H. Sakakibara, J. Kyozuka, DWARF10, an RMS1/MAX4/DAD1 ortholog, controls lateral bud outgrowth in rice. *Plant J* **51**, 1019–29 (2007).
12. C. Hamiaux R. S. Drummond B. J. Janssen S. E. Ledger J. M. Cooney R. D. Newcomb K. C. Snowden, DAD2 is an α/β hydrolase likely to be involved in the perception of the plant branching hormone, strigolactone. *Curr Biol* **22**, 2032–2036 (2012).
13. P. Stirnberg, K. van De Sande, H. M. Leyser, MAX1 and MAX2 control shoot lateral branching in Arabidopsis. *Development* **129**, 1131–1141 (2002).
14. S. Ishikawa, M. Maekawa, T. Arite, K. Onishi, I. Takamure, J. Kyozuka, Suppression of tiller bud activity in tillering dwarf mutants of rice. *Plant Cell Physiol* **46**, 79–86 (2005).
15. J. P. Stanga, S. M. Smith, W. R. Briggs, D. C. Nelson, SUPPRESSOR OF MORE AXILLARY GROWTH2 1 controls seed germination and seedling development in Arabidopsis. *Plant Physiol* **163**, 318–330 (2013).
16. F. Zhou, Q. Lin, L. Zhu, Y. Ren, K. Zhou, N. Shabek, F. Wu, H. Mao, W. Dong, L. Gan, W. Ma, H. Gao, J. Chen, C. Yang, D. Wang, J. Tan, X. Zhang, X. Guo, J. Wang, L. Jiang, X. Liu, W. Chen, J. Chu, C. Yan, K. Ueno, S. Ito, T. Asami, Z. Cheng, C. Lei, H. Zhai, C. Wu, H. Wang, N. Zheng, J. Wan, D14-SCF(D3)-dependent degradation of D53 regulates strigolactone signalling. *Nature* **504**, 406–410 (2013).
17. L. Jiang, X. Liu, G. Xiong, H. Liu, F. Chen, L. Wang, X. Meng, G. Liu, H. Yu, Y. Yuan, W. Yi, L. Zhao, H. Ma, Y. He, Z. Wu, K. Melcher, Q. Qian, H. E. Xu, Y. Wang, J. Li, DWARF 53 acts as a repressor of strigolactone signalling in rice. *Nature* **504**, 401–415 (2013).
18. H. Ma, J. Duan, J. Ke, Y. He, X. Gu, T. H. Xu, H. Yu, Y. Wang, J. S. Brunzelle, Y. Jiang, S. B. Rothbart, H. E. Xu, J. Li, K. Melcher, A D53 repression motif induces oligomerization of TOPLESS corepressors and promotes assembly of a corepressor-nucleosome complex. *Sci Adv* **3**, e1601217 (2017).
19. H. Nakamura, Y. L. Xue, T. Miyakawa, F. Hou, H. M. Qin, K. Fukui, X. Shi, E. Ito, S. Ito, S. H. Park, Y. Miyauchi, A. Asano, N. Totsuka, T. Ueda, M. Tanokura, T. Asami, Molecular mechanism of strigolactone perception by DWARF14. *Nat Commun* **4**, 2613 (2013).
20. A. de Saint Germain, G. Clavé, M. A. Badet-Denisot, J. P. Pillot, D. Cornu, J. P. Le Caer, M. Burger, F. Pelissier, P. Retailleau, C. Turnbull, S. Bonhomme, J. Chory, C. Rameau, F. D. Boyer, An histidine covalent receptor and butenolide complex mediates strigolactone perception. *Nat Chem Biol* **12**, 787–794 (2016).
21. R. Yao, Z. Ming, L. Yan, S. Li, F. Wang, S. Ma, C. Yu, M. Yang, L. Chen, Y. Li, C. Yan, D. Miao, Z. Sun, J. Yan, Y. Sun, L. Wang, J. Chu, S. Fan, W. He, H. Deng, F. Nan, J. Li, Z. Rao, Z. Lou, D. Xie, DWARF14 is a non-canonical hormone receptor for strigolactone. *Nature* **536**, 469–473 (2016).
22. D. A. Shannon, E. Weerapana, Covalent protein modification: the current landscape of residue-specific electrophiles. *Curr Opin Chem Biol* **24**, 18–26 (2015).
23. J. P. Alexander, B. F. Cravatt, The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. *J Am Chem Soc* **128**, 9699–9704 (2006).
24. D. B. Lowe, S. Magnuson, N. Qi, A. M. Campbell, J. Cook, Z. Hong, M. Wang, M. Rodriguez, F. Achebe, H. Kluender, W. C. Wong, W. H. Bullock, A. I. Salhanick, T.

- Witman-Jones, M. E. Bowling, C. Keiper, K. B. Clairmont, *In vitro* SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase. *Bioorg Med Chem Lett* **14**, 3155–3159 (2004).
25. S. Ebdrup, L. G. Sørensen, O. H. Olsen, P. Jacobsen, Synthesis and structure-activity relationship for a novel class of potent and selective carbamoyl-triazole based inhibitors of hormone sensitive lipase. *J Med Chem* **47**, 400–410 (2004).
26. A. Adibekian, B. R. Martin, C. Wang, K. L. Hsu, D. A. Bachovchin, S. Niessen, H. Hoover, B. F. Cravatt, Click-generated triazole ureas as ultrapotent *in vivo*-active serine hydrolase inhibitors. *Nat Chem Biol* **7**, 469–478 (2011).
27. M. Umehara, A. Hanada, S. Yoshida, K. Akiyama, T. Arite, N. Takeda-Kamiya, H. Magome, Y. Kamiya, K. Shirasu, K. Yoneyama, J. Kyojuka, S. Yamaguchi, Inhibition of shoot branching by new terpenoid plant hormones. *Nature* **455**, 195–200 (2008).
28. S. Toh, D. Holbrook-Smith, P. J. Stogios, O. Onopriyenko, S. Lumba, Y. Tsuchiya, A. Savchenko, P. McCourt, Structure-function analysis identifies highly sensitive strigolactone receptors in *Striga*. *Science* **350**, 203–207 (2015).
29. Y. Tsuchiya, M. Yoshimura, Y. Sato, K. Kuwata, S. Toh, D. Holbrook-Smith, H. Zhang, P. McCourt, K. Itami, T. Kinoshita, S. Hagihara, PARASITIC PLANTS. Probing strigolactone receptors in *Striga hermonthica* with fluorescence. *Science* **349**, 864–868 (2015).
30. M. Nardini, B. W. Dijkstra, Alpha/beta hydrolase fold enzymes: the family keeps growing. *Curr Opin Struct Biol* **9**, 732–737 (1999).
31. M. Kagiya, Y. Hirano, T. Mori, S. Y. Kim, J. Kyojuka, Y. Seto, S. Yamaguchi, T. Hakoshima, Structures of D14 and D14L in the strigolactone and karrikin signaling pathways. *Genes Cells* **18**, 147–160 (2013).
32. Y. Guo, Z. Zheng, J. J. La Clair, J. Chory, J. P. Noel, Smoke-derived karrikin perception by the α/β -hydrolase KAI2 from *Arabidopsis*. *Proc Natl Acad Sci U S A* **110**, 8284–8289 (2013).
33. Y. Xu, T. Miyakawa, H. Nakamura, A. Nakamura, Y. Imamura, T. Asami, Structural basis of unique ligand specificity of KAI2-like protein from parasitic weed *Striga hermonthica*. *Sci Rep* **6**, 31386 (2016).
34. K. Kamachi, T. Yamaya, T. Mae, K. Ojima, A Role for Glutamine Synthetase in the Remobilization of Leaf Nitrogen during Natural Senescence in Rice Leaves. *Plant Physiol* **96**, 411–417 (1991).
35. Y. Sugimoto, T. Ueyama, Production of (+)-5-deoxystrigol by *Lotus japonicus* root culture. *Phytochemistry* **69**, 212–217 (2008).
36. K. Fukui, S. Ito, K. Ueno, S. Yamaguchi, J. Kyojuka, T. Asami, New branching inhibitors and their potential as strigolactone mimics in rice. *Bioorg Med Chem Lett* **21**, 4905–4908 (2011).
37. W. Kabsch, XDS. *Acta Crystallogr D Biol Crystallogr* **66**, 125–132 (2010).
38. McCoy, A.J. et al. Phaser crystallographic software. *J Appl Crystallogr* **40**, 658–674 (2007).
39. P. D. Adams, P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, P. H. Zwart, PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213–221 (2010).
40. P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* **60**, 2126–2132 (2004).

41. P. D. Adams, P. V. Afonine, G. Bunkóczy, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, P. H. Zwart, Structure validation by Calpha geometry: phi,psi and Cbeta deviation. *Proteins* **50**, 437–450 (2003).
42. W. Kabsch, Solution for best rotation to relate 2 sets of vectors. *Acta Crystallographica Section a* **32**, 922–923 (1976).
43. W. DeLano, *The PyMOL Molecular Graphics System, version 1.8.6.0*, (Schroedinger, LLC, New York, 2012).
44. D. Eisenberg, E. Schwarz, M. Komaromy, R. Wall, Analysis of membrane and surface protein sequences with the hydrophobic moment plot. *J Mol Biol* **179**, 125–142 (1984).

Acknowledgments

The authors thank Prof. A.E. Babiker (Sudan University of Science and Technology) for providing the seeds of *S. hermontica* harvested in Sudan and thank Prof. J. Kyojuka (Tohoku University) for kindly providing rice SL mutants. **Funding:** This work was supported in part by a grant from the Core Research for Evolutional Science and Technology (CREST) Program of the Japan Science and Technology Agency (JST) (to T.A.); the Program for the Promotion of Basic and Applied Researches for Innovation in Bio-oriented Industry (BRAIN) (to T.A.); a JSPS Grant-in-Aid for Scientific Research (grant number 26520303 to H.N., 16H06736, 17J04676 and 17K15258 to K.H.; a JSPS Grant-in-Aid for Scientific Research on Priority Areas (grant number 18H04608 to H. N.). The synchrotron-radiation experiments were performed on BL-1A beamlines at the Photon Factory with the support from the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP17am0101071. **Author contributions:** H.N., M.T., and T.A. designed research; H.N. and W.H. performed the Y2H assay, inhibitor screening and *in planta* assays and the *in vitro* enzymatic assays. K.H., T.M., and Y.X. performed the crystal structure analysis and pull-down assay; K.J. performed the DSF assay; N.D. performed the MALDI-TOF-MS and LC-MS/MS analyses; K.K. synthesized chemicals;

701 H.N., K.H., and T.A. wrote the paper; all authors read and approved the manuscript. **Competing**
 702 **interests:** The authors declare no competing financial interests. **Data and materials availability:**
 703 The structure coordinates and structural factors are deposited in the Protein Data Bank with
 704 accession numbers of 5ZHR (D14–KK094CM complex), 5ZHS (D14–KK052CM complex) and
 705 5ZHT (D14–KK073CM complex).

706
 707

Fig. 1. Inhibition of the SL-dependent D14-D53 interactions and rice tillering. (A) Structures of 1,2,3-triazole ureas. (B) Growth of AH109 yeast transformed with pGBK-D14 and pGAD-D53 were grown for 2 days in the liquid SD+His Ade media for 2 days at 30 °C and 5 μL of each yeast culture was spotted on SD-His Ade plates containing 1 μM GR24 with 10 μM or 50 μM concentrations of the 1,2,3-triazole ureas. The bottom numbers indicate dilutions of the yeast culture. (C) Inhibition of the effect of SL on rice tillering by 1,2,3-triazole ureas. Seven-day-old *d17-1* mutant rice seedlings were treated with experimental compounds and grown for a further 7 days, and the length of the first/second tillers were measured. (D) Stimulation of rice tillering by KK094. Eight-day-old wild-type rice (cv Nipponbare) seedlings were treated with/without 10 μM KK094 and grown for a further six days. Arrow heads indicate out growing tillers. Scale bars = 3 cm. (E) Concentration-dependent effects of KK094 on plant growth and rice tillering. Eight-day-old wild-type rice (cv Nipponbare) seedlings were treated with/without KK094 and grown for a further six days; and the length of first/second tillers were measured. Error bars indicate SE of six

724 seedlings. Student's *t*-test was used to determine the significance of differences ($*p<0.05$,
725 $**p<0.01$).

726

Fig. 2. Inhibition of D14 by KK094. (A) KK094 concentration-dependently inhibits hydrolysis of GR24 by D14. GR24 and KK094 were pre-incubated at 30° C for 10 min and incubated further at 30° C for 20 min after addition of 0.33 μM of D14. Then the quantities of GR24 or ABC-OH

were monitored by LC-MS. The amount of GR24 incubated without D14 was set to 1. Error bars indicate SE of three sample replicates. Student's *t*-test was used to determine the significance of differences (**p*<0.05, ***p*<0.01). **(B)** Competitive inhibition of D14-mediated Yoshimulactone G (YLG) hydrolysis. A concentration of 0.3 μM of YLG was reacted with 0.33 μM of D14 and the fluorescent intensity was measured at an excitation wavelength of 485 nm and detected at 535 nm. The fluorescent values relative to the hydrolysis without inhibitor was shown. FU = fluorescence unit. Error bars indicate SE of three sample replicates. IC₅₀ values were calculated using the website <http://www.ic50.tk/index.html>. **(C)** KK094 alters the *V*_{max} value, not the *K*_m value, of YLG hydrolyzation by D14. Error bars indicate SE of three sample replicates. 0.3 μM of KK094-N1 reduced the *V*_{max} value by half but did not change the *K*_m value. **(D)** Preincubation with KK094-N1 reduced hydrolysis activity of D14. Pre-incubation of 0.33 μM of D14 with 0.3 μM of KK094-N1 for the indicated time and incubated for another 10 min after the addition of 0.3 μM of YLG, and the fluorescent intensity was measured. Error bars indicate SE of three sample replicates. **(E)** Melting temperature curves for D14 and the D14^{H297A} mutant protein at varying concentrations of KK094 as monitored by differential scanning fluorometry. Each line represents the average protein melt curve for three sample replicates measured in parallel.

Fig. 3. *in-vitro* pull-down assays of GST-D14 and D53 proteins, and the crystal structure of D14 in complex with KK094CM. (A) The *in-vitro* pull-down assays were performed using a two-step treatment with GR24/KK094. The interaction of D14 with D53 was detected by SDS-PAGE and Coomassie Brilliant Blue (CBB) staining. (B) Overall structure of KK094CM-bound D14. The covalently bound KK094CM is depicted in purple with van der Waals surfaces, and the catalytic S147 residue is shown as a stick model. (C) The electron density map of the covalently bound KK094CM to S147. KK094CM is shown as a stick model (purple), along with the $2F_o - F_c$ map contoured at 1.0σ (gray). (D) Binding site of KK094CM in the catalytic pocket of D14. The residues involved in the interaction with KK094CM ($< 4.5 \text{ \AA}$) are represented by a line model. Water molecules are shown as red balls, and the blue broken line indicates a hydrogen bond.

762

763

764

765

766

767

768

Fig. 4. Covalent binding of KK094CM to S147 (A) D14 was incubated without (upper panel) or with (lower panel) GR24 and analyzed by MALDI-TOF MS. (B) The reaction mixture of D14 and GR24 without or with KK094 (-KK094/+KK094, respectively) was dialyzed against a 50 mM NH_4HCO_3 solution. The dialyzed sample was digested with trypsin and analyzed using LC-

769 MS/MS. MS/MS spectra of peptides corresponding to peptides 141–159
 770 ($^{141}\text{CAFVGHSVSAMIGILASIR}^{159}$; m/z 1932.446 for -KK094 (upper), m/z 2077.454 for +KK094
 771 (lower)) are shown. Peaks of the ions y13 and y15 indicate that the Ser-residue (red letter) is
 772 covalently modified by KK094CM.
 773

Fig. 5. Agonistic effects of KK073 on D14–D53/D14–D3 interactions. (A) Structures of KK052 and KK073 are shown on the right. Y2H: Growth of AH109/pGBK-D14–pGAD-D53 or AH109/pGBK-D14–pGAD-SLR1 on SD-His Ade plates containing experimental compounds for 4 days at 30°C. KK073 showed an agonistic effect (in red squares) and KK052 showed antagonism (in blue squares). Y3H: Growth of AH109/ pBridge-BD:D14-M:OSK1–pGAD-D3 or AH109/ pBridge-BD:D14-M:OSK1–pGADT7 on SD-His Ade Met plates containing experimental compounds for 4 days at 30°C. (B) *In-vitro* pull-down assays of GST–D14 and D53

using a two-step treatment with GR24/KK052/KK073. The interaction of D14 with D53 was
detected by SDS-PAGE and CBB staining.

Fig. 6. KK052CM and KK073CM covalently binds to D14. (A–C) Crystal structures of D14 in complex with KK052CM or KK073CM. Overall structures (A), electron density maps (B) and binding sites (C) of KK052CM (green) and KK073CM (pink). The orientation and structural representation are the same as in Fig. 3A–D. (D) Comparison of the ligand binding sites of KK073CM-bound D14 (pink) and D-OH-bound D14 (PDB ID 3WIO) (blue). The residues involved in the interaction with the trifluoromethyl group of KK073 and D-OH are represented by line models, and the broken lines indicate hydrogen bonds. The orientation is the same as in (C). The r.m.s.d. for the C α atoms was 0.38 Å. (E) The hydrophobicity of the surface residues in KK073CM-bound D14 and D-OH-bound D14 (PDB ID 3WIO). Hydrophobic residues are shown

798 in red, whereas hydrophilic sites are shown in white. KK073CM and D-OH are depicted in van
799 der Waals surfaces. The trifluoromethyl group of KK073 protruded out of the pocket and
800 generated a polar patch in the hydrophobic surface of D14.

801

802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822

Supplementary Materials

- fig. S1. Inhibition of the SL-dependent D14–D53 interaction by KK007-and KK004-derivatives.
- fig. S2. Effects of KK compounds on plant growth.
- fig. S3. Inhibition of the SL-dependent D14–D53 interactions and rice tillering by KK122.
- fig. S4. Inhibition of the SL-dependent D14–D53 interactions and rice tillering by KK094-derivatives.
- fig. S5. Inhibition of *Striga* seed germination and a *Striga* SL receptor, ShHTL7, by KK094.
- fig. S6. LC-MS analyses of GR24- or KK094N1-hydrolysis by D14.
- fig. S7. Structural comparisons.
- fig. S8. MALDI-TOF-MS analysis of trypsin-treated D14 with or without KK094.
- fig. S9. Inhibition or stimulation of the SL-dependent D14–SLR1/D14–D53 interaction by KK052-derivatives.
- fig. S10. KK073 showed antagonism of the suppression of rice tillering induced by strigolactone.
- table S1. X-ray data collection and refinement statistics.
- table S2. Deduced peptide mass values of D14 fragments digested with trypsin.
- table S3. Theoretical mass values of peptide 141–159 (¹⁴¹CAFVGHSVSAMIGILASIR¹⁵⁹).

Supplementary Notes

fig. S1. Inhibition of the SL-dependent D14–D53 interaction by KK007- and KK004-derivatives. (A) Structures of KK007N1-derivatives. Various substituents were introduced onto the 4-position of the 1,2,3-triazole group of KK007N1. (B) Growth of AH109/pGBK-D14–pGAD-D53 on SD-His Ade plates containing 1 μ M GR24 with 10 μ M or 50 μ M 1,2,3-triazole ureas for 4 days at 30 °C. (C) Structures of KK004-derivatives. The morpholine structure derived from KK004 (mixture of N1- and N2-compounds; shown in the dashed box) was modified by the addition of various substituents. (D) Growth of AH109/pGBK-D14–pGAD-D53 on an SD-His Ade plate containing 1 μ M GR24 with 10 μ M or 10 μ M of 1,2,3-triazole ureas for 4 days at 30 °C.

fig. S2. Effects of KK compounds on plant growth. Seven-day-old *dl7-1* mutant rice seedlings were treated with experimental compounds, grown for a further 7 days, then plant heights were measured. Error bars indicate SE of six seedlings. Unpaired two-Student's *t*-test was used to determine the significance of differences (* $p < 0.05$, ** $p < 0.01$).

fig. S3. Inhibition of the SL-dependent D14–D53 interactions and rice tillering by KK122.

(A) Growth of AH109 yeast transformed with pGBK-D14 and pGAD-T7/pGAD-D53/pGAD-SLR1 on an SD-His Ade plate containing 10 μM GR24 with 10 μM KK094N1/KK122 for 4 days at 30 °C. (B) Inhibition of the effect of SL on rice tillering by KK122. Seven-day-old *d17-1* mutant rice seedlings were treated with experimental compounds and grown for a further 7 days, and plant heights and the length of the first/second tillers were measured. Error bars indicate SE of six seedlings. Unpaired two-tailed Student's *t*-test was used to determine the significance of differences (***p*<0.01).

KK094N1-derivatives

KK094N2-derivatives

		R ₁ = CH ₃	R ₂ = CH ₃	R ₃ = NO ₂ Cl CH ₃	R ₄ = NO ₂ Cl CH ₃	R ₅ = NO ₂ Cl CH ₃	R ₆ = NO ₂ Cl
	KK094 (26)	29	30	31 32 33	34 35 36	37 38 39	40 41
Inhibition of SL-induced D14-D53 complex formation in Y2H assay	+++	-	++	- - -	- - -	- - -	- -
Promotion of rice tillering in wild-type rice	+++	-	++	- - -	- - -	- - -	- -

fig. S4. Inhibition of the SL-dependent D14–D53 interactions and rice tillering by KK094-derivatives. Upper line in the bottom column: Growth of AH109 yeast transformed with pGBK-D14 and pGAD-T7/pGAD-D53 on an SD-His Ade plate containing 1 μ M GR24 with experimental compounds for 4 days at 30° C. The extent of growth inhibition is indicated by – to +++ (– no inhibition; ++ partial inhibition; +++ complete inhibition). Lower line in the bottom column: Inhibition of the effect of SL on rice tillering. Seven-day-old *d17-1* mutant rice seedlings were treated with/without 1 μ M GR24 and 10 μ M KK094-derivatives and grown for 7 days before the length of second tillers were measured. The extent of tillering bud growth promotion is presented by – to +++ (– no promotion [2nd tiller length = 0 cm]; + weak promotion [2nd tiller length = 0–1.0 cm]; ++ intermediate inhibition [2nd tiller length = 1.0–3.0 cm]; +++ strong promotion [2nd tiller length > 3.0 cm]).

fig. S5. Inhibition of *Striga* seed germination and a *Striga* SL receptor, ShHTL7, by KK094.

(A) KK094 concentration-dependently inhibits seed germination of *Striga hermonthica*.

Germination ratios of *Striga* seeds treated with 1 μM of GR24 and KK094 at the concentrations shown. Error bars indicate SE of three independent experiments. Unpaired two-tailed Student's *t*-test was used to determine the significance of differences with the germination rate of KK094-non-treated seeds (***p* < 0.01). (B) Competitive inhibition of ShHTL7-mediated YLG hydrolysis. Following reaction of 0.3 μM of YLG with 0.33 μM of D14, the fluorescent intensity was measured at the excitation wavelength of 485 nm and detected at a wavelength of 535 nm. The fluorescent values relative to the hydrolysis without inhibitor is shown. FU = fluorescence unit. *IC*₅₀ values were calculated using the website: <http://www.ic50.tk/index.html>.

fig. S6. LC-MS analyses of GR24- or KK094N1-hydrolysis by D14. (A) The reaction formula of D14-mediated hydrolysis of GR24. (B–D) GR24 or KK094 was pre-incubated at 30 °C for 10 min and incubated further at 30 °C for 20 min after addition of 0.33 μM of D14. Then quantities of GR24 or ABC-OH were monitored using LC-MS (B, C). Quantities of KK094N1 were also monitored by LC-MS (D). Error bars indicate SE of three sample replicates.. Unpaired two-tailed Student's *t*-test was used to determine the significance of differences (* $p < 0.05$, ** $p < 0.01$).

fig. S7. Structural comparisons. (A) KK094CM-bound D14, KK042CM-bound D14, and KK073CM-bound D14 are superimposed on apo-D14 (PDB ID 3VXK) (white). The orientation and color coding are the same as in Fig. 3A and Fig. 6A. Each r.m.s.d. for the C α atoms was 0.16 Å (KK094CM), 0.35 Å (KK052CM), and 0.35 Å (KK073CM). (B) The close-up view of the ligand-binding sites in (A). The orientation and structural representation are the same as in Fig. 3A and 6C. Water molecules from apo-D14 are shown as white balls.

fig. S8. MALDI-TOF-MS analysis of trypsin-treated D14 with or without KK094. (A) D14 was incubated without (upper panel) or with (lower panel) KK094. The reaction mixture of D14 without or with KK094 (-KK094/+KK094, respectively) was dialyzed against 50 mM NH_4HCO_3 solution. Dialyzed sample was digested with trypsin and analyzed using MALDI-TOF-MS. (B) Magnification of the red box in panel (A). The fragment corresponding to the peptide 141–159 ($^{141}\text{CA FVGHVSAMIGILASIR}^{159}$; m/z 1932.446) was detected under the -KK094 condition but was not detected under the +KK094 condition. On the contrary, the peptide fragment with a molecular mass of 2077.454, corresponding to the peptide 141–159 with covalently-bound KK094-CM was detected when D14 was incubated with KK094.

A

B

fig. S9. Inhibition or stimulation of the SL-dependent D14–SLR1/D14–D53 interaction by KK052-derivatives. (A) Structures of KK052-derivatives are shown on the right. The morpholine structure derived from KK052 (mixture of N1- and N2-compounds; shown in the dashed box) were modified by various substituents. Growth of AH109/pGBK-D14–pGAD-D53 or AH109/pGBK-D14–pGAD-SLR1 on an SD-His Ade plate containing experimental compounds for 4 days at 30 °C. Three compounds showed an agonist effect (in red squares), and two showed antagonism (in blue squares). (B) Structures of KK182 (a mixture of N1- and N2-compounds) and growth of AH109/pGBK-D14–pGAD-D53 on an SD-His Ade plate containing experimental compounds for 4 days at 30 °C.

fig. S10. KK073 showed antagonism of the suppression of rice tillering induced by strigolactone. (A) KK073 produced attenuation of the tillering inhibition induced by GR24. Seven-day-old *d10-1* mutant rice seedlings were treated with experimental compounds and grown for a further 2 weeks, then the length of second/third tillers were measured. Error bars indicate SE of three to six seedlings. Unpaired two-tailed student's *t*-test was used to determine the significance of differences (** $p < 0.01$). (B) Melting temperature curves for D14 and D14^{H297A} mutant proteins at varying concentrations of KK073 as monitored by differential scanning fluorimetry. Each line represents the average protein melt curve for three replicate samples measured in parallel.

950

table S1. X-ray data collection and refinement statistics.

	D14–KK094CM complex (5ZHR)	D14–KK052CM complex (5ZHS)	D14–KK073CM complex (5ZHT)
Data collection			
Space group	$P2_12_12_1$	$P3_22_1$	$P3_22_1$
Cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	48.25, 88.64, 119.38	48.97, 48.97, 192.20	49.35, 49.35, 192.47
α , β , γ (°)	90, 90, 90	90, 90, 120	90, 90, 120
Resolution (Å)	1.45 (1.54 - 1.45)	1.49 (1.58 - 1.49)	1.53 (1.62 - 1.53)
No. of observations	846,524	434,216	376,778
No. of unique reflections	90,592	44,884	41,947
R_{merge}^a (%)	4.7 (27.4)	6.1 (39.0)	5.8 (39.6)
$I/\sigma I$	26.3 (5.9)	20.0 (4.3)	20.1 (3.1)
$CC_{1/2}^b$ (%)	100.0 (95.2)	99.9 (96.2)	99.9 (93.4)
Completeness (%)	99.0 (94.0)	99.9 (99.2)	99.5 (97.3)
Redundancy	9.3 (6.8)	9.7 (9.5)	9.0 (5.8)
Refinement			
Resolution (Å)	49.51 - 1.45	41.41 - 1.49	41.72 - 1.53
No. of used reflections	173,170	84,082	78,145
R_{work}^c / R_{free}^d (%)	16.6/19.9	18.8/21.1	19.5/22.1
No. of atoms			
Protein	4,102	2,046	2,051
Ligand	22	14	18
Water	526	280	283
<i>B</i> factors (Å ²)			
Protein	16.2	21.5	24.1
Ligand	12.2	16.0	20.0
Water	26.2	31.9	34.8
r.m.s. deviations			
Bond lengths (Å)	0.009	0.005	0.004
Bond angles (°)	1.215	0.930	0.887
Ramachandran plot (%)			
Favored	97.5	97.7	97.3
Allowed	2.5	2.3	2.7
Outliers	0.0	0.0	0.0

Values in parentheses correspond to the highest-resolution shell.

^a $R_{\text{merge}} = \sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$.

^b $CC_{1/2}$ is the percentage of correlation between intensities from random half-datasets.

^c $R_{\text{work}} = \sum_{hkl} |F_o(hkl) - F_c(hkl)| / \sum_{hkl} F_o(hkl)$.

^d R_{free} is the R_{work} calculated for 5% of the data set not included in refinements.

951

952

953

954

955

table S2. Deduced peptide mass values of D14 fragments digested with trypsin.

<i>Num</i>	<i>From-To</i>	<i>MH⁺</i>	<i>Mass</i>	<i>Sequence</i>
1	1-5	429.25	428.24	GPGAK
2	6-13	968.63	967.62	LLQILNVR
3	14- 20	703.37	702.37	VVGSGER
4	21- 37	1845.92	1844.92	VVVLSHGFGTDQSAWSR
5	38- 44	861.52	860.51	VLPYLTR
6	45- 47	427.2	426.2	DHR
7	48- 67	2266.1	2265.09	VVLYDLVCAGSVNPDHFDNR
8	68- 68	175.12	174.11	R
9	69- 87	2181.11	2180.1	YDNLDAYVDDLLAILDALR
10	88- 90	385.26	384.25	IPR
11	91-109	1932.02	1931.01	CAFVGHSVSAMIGILASIR
12	110-116	846.48	845.48	RPDLFAK
13	117-125	925.58	924.58	LVLIGASPR
14	126-177	5624.6	5623.59	FLNDSYHGGFELEEIQQVFDAMGANYSAWATGYAPLAVGADVPAAVQEFSSR
15	178-196	2249.16	2248.15	TLFNMRPDISLHVCQTVFK
16	197-200	504.28	503.27	TDLR
17	201-207	731.42	730.42	GVLGMVR
18	208-217	1073.58	1072.57	APCVVVQTTR
19	218-230	1319.72	1318.71	DVSVPASVAAYLK
20	231-236	610.34	609.33	AHLGGR
21	237-262	2857.56	2856.55	TTVEFLQTEGHLPHLSAPSLAQVLR
22	263-263	175.12	174.11	R
23	264-267	430.28	429.27	ALAR
24	268-268	182.08	181.07	Y
25	1-13	1378.85	1377.85	GPGAKLLQILNVR
26	6-20	1652.98	1651.97	LLQILNVRVVGSGER
27	14- 37	2530.28	2529.27	VVGSGERVVVLSHGFGTDQSAWSR
28	21- 44	2688.43	2687.42	VVVLSHGFGTDQSAWSRVLPYLTR
29	38- 47	1269.71	1268.7	VLPYLTRDHR

30	45- 67	2674.28	2673.28	DHRVVLYDLVCAGSVNPDHFDFFR
31	48- 68	2422.2	2421.19	VVLYDLVCAGSVNPDHFDFFR
32	68- 87	2337.21	2336.2	RYDNLDAYVDDLLAILDALR
33	69- 90	2547.35	2546.34	YDNLDAYVDDLLAILDALRIPR
34	88-109	2298.26	2297.25	IPRCAFVGHSVSAMIGILASIR
35	91-116	2759.48	2758.48	CAFVGHSVSAMIGILASIRRPDLFAK
36	110-125	1753.05	1752.04	RPDLFAKLVLIGASPR
37	117-177	6531.17	6530.16	LVLIGASPRFLNDSYHGGFELEEIQQVFDAMGANYSAWATGYAPLAVGADVPAAVQEFSR
38	126-196	7854.74	7853.73	FLNDSYHGGFELEEIQQVFDAMGANYSAWATGYAPLAVGADVPAAVQEFS RTLFNMRPDISLHVCQTVFK
39	178-200	2734.42	2733.41	TLFNMRPDISLHVCQTVFKTDLR
40	197-207	1216.68	1215.68	TDLRGVLGMVR
41	201-217	1785.98	1784.98	GVLGMVRAPCVVQTTTR
42	208-230	2374.28	2373.27	APCVVQTTTRDVSPASVAAYLK
43	218-236	1911.04	1910.04	DVSPASVAAYLKAHLGGR
44	231-262	3448.88	3447.87	AHLGGRTTVEFLQTEGHLPHLSAPSLAQVLR
45	237-263	3013.66	3012.65	TTVEFLQTEGHLPHLSAPSLAQVLR
46	263-267	586.38	585.37	RALAR
47	264-268	593.34	592.33	ALARY

956

957

958

959 **table S3. Theoretical mass values of peptide 141–159 (¹⁴¹CAFVGHSVSAMIGILASIR¹⁵⁹).**

960

Theoretical mass value: CAFVGHSVSAMIGILASIR				
Mass	Fragment		Fragment	Mass
104.017	b1	Cys	y17	-
175.054	b2	Ala	y16	1829.011
322.123	b3	Phe	y15	1757.974
421.191	b4	Val	y14	1610.905
478.212	b5	Gly	y13	1511.837
615.271	b6	His	y12	1454.815
702.303	b7	Ser	y11	1317.756
801.372	b8	Val	y10	1230.724
888.404	b9	Ser	y9	1131.656
959.441	b10	Ala	y8	1044.624
1090.481	b11	Met	y7	973.587
1203.565	b12	Ile	y6	842.546
1260.587	b13	Gly	y5	729.462
1373.671	b14	Ile	y4	672.441
1486.755	b15	Leu	y3	559.357
1557.792	b16	Ala	y2	446.273
1644.824	b17	Ser	y1	375.236
1757.908	b18	Ile	y0	288.204
-	b19	Arg	y1	175.120

961

962

963
964

Theoretical mass value: CAFVGHSVSAMIGILASIR+KK094CM				
Mass	Fragment		Fragment	Mass
104.017	b1	Cys	y17	-
175.054	b2	Ala	y16	1974.064
322.123	b3	Phe	y15	1903.026
421.191	b4	Val	y14	1755.958
478.212	b5	Gly	y13	1656.890
615.271	b6	His	y12	1599.868
847.356	b7	Ser	y11	1462.809
946.425	b8	Val	y10	1230.724
1033.457	b9	Ser	y9	1131.656
1104.494	b10	Ala	y8	1044.624
1235.534	b11	Met	y7	973.587
1348.618	b12	Ile	y6	842.546
1405.640	b13	Gly	y5	729.462
1518.724	b14	Ile	y4	672.441
1631.808	b15	Leu	y3	559.357
1702.845	b16	Ala	y2	446.273
1789.877	b17	Ser	y1	375.236
1902.961	b18	Ile	y0	288.204
-	b19	Arg	y1	175.120

965 * Shaded cells represent that these fragments were detected. Mass values written in bold letters represent that these
966 fragments covalently bind to KK094CM.

967

Supplementary Notes

General Procedure: NMR spectra (^1H , ^{13}C) were recorded at 500 MHz on a JNM-A500 spectrometer (JEOL, Tokyo, Japan) or a VNMR500 spectrometer (Agilent, CA). High resolution mass spectra (HRMS) were determined by electrospray ionization coupled to a time-of-flight analyser (Triple TOF 5600+ system, SCIEX, MA).

KK002-N1 (1), KK002-N2 (2): *N,N*-diethyl-1*H*-1,2,3-triazole-1-carboxamide (**1**), *N,N*-diethyl-2*H*-1,2,3-triazole-2-carboxamide (**2**).

The mixture of diethylcarbamoyl chloride (136 mg, 1 mmol), 1*H*-1,2,3-triazole (83 mg, 1.2 mmol) and *N,N*-dimethyl-4-aminopyridine (DMAP) (cat.) in tetrahydrofuran (THF)/triethylamine (NEt_3) (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/ethyl acetate (EtOAc) 7:3 to 6:4) giving KK002-N1 (**1**) as colorless oil (73mg, 43%) and KK002-N2 (**2**) as a white solid (55 mg, 33%).

KK002-N1 (1); ^1H NMR (500 MHz, CDCl_3): δ 8.19 (d, J = 1.0 Hz, 1H), 7.72 (d, J = 1.0 Hz, 1H), 3.80-3.40 (m, 4H), 1.33 (t, J = 7.0 Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3): δ 148.7, 132.7, 125.2, 44.3, 14.1. HRMS (m/z): calcd. for $\text{C}_7\text{H}_{12}\text{N}_4\text{ONa}$ [$\text{M}+\text{Na}$] $^+$: 191.0903; found, 191.0905.

KK002-N2 (2); ^1H NMR (500 MHz, CDCl_3): δ 7.80 (s, 2H), 3.75-3.30 (m, 4H), 1.29 (t, J = 7.0 Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3): δ 135.6, 43.1, 12.4. HRMS (m/z): calcd. for $\text{C}_7\text{H}_{12}\text{N}_4\text{O}$ [$\text{M}+\text{Na}$] $^+$: 191.0903; found, 191.0911.

KK003-N1 (3), KK003-N2 (4): *N,N*-diphenyl-1*H*-1,2,3-triazole-1-carboxamide (**3**), *N,N*-diphenyl-2*H*-1,2,3-triazole-2-carboxamide (**4**).

The mixture of diphenylcarbamoyl chloride (280 mg, 1.21 mmol), 1*H*-1,2,3-triazole (100 mg, 1.45 mmol) and DMAP (cat.) in THF/ NEt_3 (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK003-N1 (**3**) (197 mg, 62%) as a white solid and KK003-N2 (**4**) (121mg, 38%) as a white solid.

KK003-N1 (3); ^1H NMR (500 MHz, CDCl_3): δ 8.11 (d, J = 1.3 Hz, 1H), 7.59 (d, J = 1.3 Hz, 1H), 7.38-7.33 (m, 4H), 7.30-7.25 (m, 2H), 7.23-7.18 (m, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ 148.81, 142.30, 132.74, 129.51, 127.49, 126.48, 124.51.

KK003-N2 (4); ^1H NMR (500 MHz, CDCl_3): δ 8.11 (d, J = 1.3 Hz, 1H), 7.59 (d, J = 1.3 Hz, 1H),

7.38-7.33 (m, 4H), ¹H NMR (500 MHz, CDCl₃): δ 7.61 (s, 2H), 7.30-7.34 (m, 4H), 7.22-7.26 (m, 2H), 7.16-7.18 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 149.31, 142.55, 136.17, 129.32, 127.02, 126.30.

KK004-N1 (5), KK004-N2 (6): morpholino(1*H*-1,2,3-triazol-1-yl)methanone (**5**), morpholino(2*H*-1,2,3-triazol-2-yl)methanone (**6**).

The mixture of 4-morpholinecarbonyl chloride (150 mg, 1 mmol), 1*H*-1,2,3-triazole (83 mg, 1.2 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK004-N1 (**5**) (53 mg, 29%) as a white solid and KK004-N2 (**6**) (26 mg, 14%) as a white solid.

KK004-N1 (5); ¹H NMR (500 MHz, CDCl₃): δ 8.19 (d, *J* = 1.1 Hz, 1H), 7.74 (d, *J* = 1.1 Hz, 1H), 4.17-3.66 (m, 8H). ¹³C NMR (125 MHz, CDCl₃): δ 133.0, 125.4, 66.6, 48.4, 45.7. HRMS (*m/z*): calcd. for C₇H₁₀N₄O₂ [M+Na]⁺: 205.0696; found, 205.0695.

KK004-N2 (6); ¹H NMR (500 MHz, CDCl₃): δ 7.83 (s, 2H), 4.10-3.65 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 136.2, 66.6, 48.4, 45.8. HRMS (*m/z*): calcd. for C₇H₁₀N₄O₂ [M+Na]⁺: 205.0696; found, 205.0694.

KK007-N1 (7), KK007-N2 (8): pyrrolidin-1-yl(1*H*-1,2,3-triazol-1-yl)methanone (**7**), pyrrolidin-1-yl(2*H*-1,2,3-triazol-2-yl)methanone (**8**).

The mixture of 1-pyrrolidinecarbonyl chloride (100 mg, 0.8 mmol), 1*H*-1,2,3-triazole (124 mg, 1.8 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK007-N1 (**7**) (68 mg, 55%) as a white solid and KK007-N2 (**8**) (36 mg, 29%) as a white solid.

KK007-N1 (7); ¹H NMR (500 MHz, CDCl₃): δ 8.31 (d, *J* = 1.4 Hz, 1H), 7.72 (d, *J* = 1.4 Hz, 1H), 4.04 (t, *J* = 6.5 Hz, 2H), 3.74 (t, *J* = 6.7 Hz, 2H), 2.08-1.95 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 147.12, 132.59, 124.65, 50.25, 48.92, 26.48, 23.90. HRMS (*m/z*): calcd. for C₇H₁₀N₄O [M+Na]⁺: 189.0747; found, 189.0751.

KK007-N2 (8); ¹H NMR (500 MHz, CDCl₃): δ 7.81 (s, 2H), 3.84 (t, *J* = 6.4 Hz, 2H), 3.75 (t, *J* = 6.5 Hz, 2H), 2.02-1.94 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 135.80, 50.02, 48.62, 26.44, 24.12. HRMS (*m/z*): calcd. for C₇H₁₀N₄O [M+Na]⁺: 189.0747; found, 189.0749.

KK020 (9): (4-benzyl-1*H*-1,2,3-triazol-1-yl)(pyrrolidin-1-yl)methanone.

The mixture of 1-pyrrolidinecarbonyl chloride (190 mg, 1.4 mmol), 4-benzyl-1*H*-1,2,3-triazole (226 mg, 1.4 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK020 (**9**) (86 mg, 24%) as yellow oil.

¹H NMR (500 MHz, CDCl₃): δ 7.91 (s, 1H), 7.21-7.34 (m, 5H), 4.11 (s, 2H), 4.01 (t, *J* = 6.3 Hz, 2H), 3.69 (t, *J* = 6.6 Hz, 2H), 1.92-2.04 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 147.2, 146.5, 138.3, 128.7, 128.7, 126.7, 50.2, 48.9, 31.9, 26.5, 23.9. HRMS (*m/z*): calcd. for C₁₄H₁₆N₄O [M+H]⁺: 257.1397; found, 257.1403.

KK021 (10): (4-(6-methoxynaphthalen-2-yl)-1*H*-1,2,3-triazol-1-yl)(pyrrolidin-1-yl)methanone.

The mixture of 1-pyrrolidinecarbonyl chloride (190 mg, 1.4 mmol), 4-(6-methoxynaphthalen-2-yl)-1*H*-1,2,3-triazole (338 mg, 1.5 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK021 (**10**) (47 mg, 10%) as a white solid.

¹H NMR (500 MHz, CDCl₃): δ 8.56 (s, 1H), 8.34 (s, 1H), 7.92 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.86-7.77 (m, 2H), 7.21-7.14 (m, 2H), 4.10 (t, *J* = 6.5 Hz, 2H), 3.94 (s, 3H), 3.77 (t, *J* = 6.5 Hz, 2H), 2.09-1.97 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 158.13, 147.19, 146.62, 134.60, 129.81, 128.91, 127.51, 124.82, 124.79, 124.31, 120.01, 119.44, 105.78, 55.33, 50.34, 49.01, 26.58, 23.96. HRMS (*m/z*): calcd. for C₁₈H₁₈N₄O₂ [M+H]⁺: 323.1503; found, 323.1498.

KK022 (11): (4-phenyl-1*H*-1,2,3-triazol-1-yl)(pyrrolidin-1-yl)methanone.

The mixture of 1-pyrrolidinecarbonyl chloride (417 mg, 3.1 mmol), 4-phenyl-1*H*-1,2,3-triazole (300 mg, 2.1 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/ EtOAc 7:3 to 6:4) giving KK022 (**11**) (243 mg, 48%) as a white solid.

¹H NMR (500 MHz, CDCl₃): δ 8.49 (s, 1H), 7.91-7.86 (m, 2H), 7.49-7.43 (m, 2H), 7.41-7.34 (m, 1H), 4.07 (t, *J* = 6.7 Hz, 2H), 3.75 (t, *J* = 6.7 Hz, 2H), 2.09-1.95 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 147.08, 146.35, 129.60, 129.06, 128.91, 128.78, 128.60, 125.88, 120.17, 50.28, 48.96, 26.52, 23.89. HRMS (*m/z*): calcd. for C₁₃H₁₄N₄O [M+H]⁺: 243.1240; found, 243.1238.

KK025 (12): (4-(4-phenoxyphenyl)-1*H*-1,2,3-triazol-1-yl)(pyrrolidin-1-yl)methanone.

The mixture of 1-pyrrolidinecarbonyl chloride (480 mg, 3.6 mmol), 4-(4-phenoxyphenyl)-1*H*-1,2,3-triazole (568 mg, 2.4 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight

at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK025 (**12**) (219 mg, 27%) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 8.44 (s, 1H), 7.84 (dt, *J* = 9.2, 2.4 Hz, 2H), 7.43-7.30 (m, 2H), 7.18-7.11 (m, 1H), 7.11-7.01 (m, 4H), 4.07 (t, *J* = 6.6 Hz, 2H), 3.75 (t, *J* = 6.6 Hz, 2H), 2.09-1.96 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 157.80, 156.70, 147.09, 145.92, 129.82, 127.42, 124.61, 123.62, 119.68, 119.20, 118.98, 50.28, 48.97, 26.54, 23.90. HRMS (*m/z*): calcd. for C₁₃H₁₂N₄OCl₂ [M+H]⁺: 311.0461; found, 311.0460.

KK030 (13): (4-(3,4-dichlorophenyl)-1*H*-1,2,3-triazol-1-yl)(pyrrolidin-1-yl)methanone. The mixture of 1-pyrrolidinecarbonyl chloride (810 mg, 6.1 mmol), 4-(3,4-dichlorophenyl)-1*H*-1,2,3-triazole (865 mg, 4.0 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK030 (**13**) (407 mg, 32%) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 8.51 (s, 1H), 8.00 (d, *J* = 1.9 Hz, 1H), 7.71 (dd, *J* = 8.3, 1.9 Hz, 1H), 7.52 (d, *J* = 8.3 Hz, 1H), 4.07 (t, *J* = 6.5 Hz, 2H), 3.76 (t, *J* = 6.7 Hz, 2H), 2.10-1.96 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 146.76, 144.26, 133.20, 132.53, 130.94, 129.66, 127.68, 125.02, 120.75, 50.29, 49.06, 26.53, 23.90. HRMS (*m/z*): calcd. for C₁₉H₁₈N₄O₂ [M+H]⁺: 335.1503; found, 335.1505.

KK031 (14): pyrrolidin-1-yl(4-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,3-triazol-1-yl)methanone. The mixture of 1-pyrrolidinecarbonyl chloride (432 mg, 3.2 mmol), 4-(4-(trifluoromethoxy)phenyl)-1*H*-1,2,3-triazole (494 mg, 2.2 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK031 (**14**) (264 mg, 38%) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 8.50 (s, 1H), 7.94-7.90 (m, 2H), 7.34-7.28 (m, 2H), 4.08 (t, *J* = 6.6 Hz, 2H), 3.76 (t, *J* = 6.6 Hz, 2H), 2.10-1.97 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 149.29, 146.92, 145.14, 128.41, 127.34, 121.43, 120.42, 119.39, 50.30, 49.03, 26.54, 23.90. HRMS (*m/z*): calcd. for C₁₄H₁₃N₄O₂F₃, [M+H]⁺: 327.1063, found, 327.1068.

KK032 (15): (4-(3,5-difluorophenyl)-1*H*-1,2,3-triazol-1-yl)(pyrrolidin-1-yl)methanone. The mixture of 1-pyrrolidinecarbonyl chloride (817 mg, 6.1 mmol), 4-(3,5-difluorophenyl)-1*H*-1,2,3-triazole (739 mg, 4.1 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a

silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK032 (**15**) (264 mg, 38%) as a white solid.

¹H NMR (500 MHz, CDCl₃): δ 8.54 (s, 1H), 7.45-7.39 (m, 2H), 6.82 (tt, *J* = 8.8, 2.3 Hz, 1H), 4.07 (t, *J* = 6.6 Hz, 2H), 3.76 (t, *J* = 6.6 Hz, 2H), 2.10-1.97 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 164.38, 162.40, 146.73, 144.45, 132.76, 121.15, 108.80, 103.84, 50.30, 49.07, 26.52, 23.89.

HRMS (*m/z*): calcd. for C₁₃H₁₂N₄OF₂ [M+Na]⁺: 279.1052; found, 279.1054;

KK052 (16): The mixture of (4-phenylpiperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone (N1-isomer) and (4-phenylpiperazin-1-yl)(2*H*-1,2,3-triazol-2-yl)methanone (N2-isomer).

The mixture of 4-phenylpiperazine-1-carbonyl chloride (191 mg, 0.9 mmol), 4-(3,5-difluorophenyl)-*NH*-1,2,3-triazole (70 mg, 1.0 mmol) and DMAP (cat.) in THF/NEt₃ (5:1, 2 mL) was stirred overnight at 60 °C. The solvent was removed under vacuum and the resulting residue was purified on a silica gel column (Hexane/EtOAc 7:3 to 6:4) giving KK052 (**16**) (215 mg, 98%, NMR ratio N1-isomer:N2-isomer=2:1) as a white solid.

KK052-N1: ¹H NMR (500 MHz, CDCl₃): δ 8.21 (d, *J* = 1.1 Hz, 1H), 7.75 (d, *J* = 1.1 Hz, 1H), 7.33-7.28 (m, 2H), 6.98-6.91 (m, 3H), 4.25-3.85 (m, 4H), 3.43-3.24 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 150.58, 148.05, 132.99, 129.30, 125.44, 120.86, 116.75, 49.61, 49.31, 47.81, 45.47.

HRMS (*m/z*): calcd. for C₁₃H₁₅N₅O [M+H]⁺: 258.1349; found, 258.1347.

KK052-N1: ¹H NMR (500 MHz, CDCl₃) δ 7.85 (s, 2H), 7.33-7.28 (m, 2H), 6.97-6.91 (m, 3H), 4.03-3.83 (m, 4H), 3.44-3.19 (m, 4H). ¹³C NMR (126 MHz, CDCl₃) δ 150.69, 148.93, 136.17, 129.28, 120.79, 116.76, 49.43, 47.56, 45.29. HRMS (*m/z*): calcd. for C₁₃H₁₅N₅O [M+H]⁺: 258.1349; found, 258.1348.

KK053-N1 (17): (4-(2-chlorophenyl)piperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

1-(2-chlorophenyl)piperazine (150 mg, 0.8 mmol) and *N,N*-diisopropylethylamine (296 mg, 2.3 mmol) were added to the triphosgene (113 mg, 0.4 mmol) solution in THF (5 mL) keeping the temperature inside <10 °C and cooled to 0 °C. The reaction was stirred for 15 min on ice. After adding iced water, the reaction solution was extracted with EtOAc twice. The EtOAc layer was combined, dehydrated with Na₂SO₄ and the solvent was removed under vacuum and the carbamoyl chloride intermediate was obtained. The resulting residue was dissolved in THF (5 mL) and *N,N*-diisopropylethylamine (713 mg, 5.5 mmol), 1*H*-1,2,3-triazole (63 mg, 0.9 mmol) and DMAP (cat.) were added on ice and stirred overnight at room temperature (rt). Then the solvent was removed under vacuum and the resulting residue was dissolved and extracted with EtOAc and water twice. The EtOAc layer was combined and the solvent was removed under

vacuum and the resulting residue was purified on a silica gel column (Hexane:AcOEt=7:3 to 1:1) giving KK053-N1 (**17**) (88 mg, 40%) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 8.21 (d, *J* = 1.3 Hz, 1H), 7.75 (d, *J* = 1.3 Hz, 1H), 7.40 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.27-7.23 (m, 1H), 7.08-7.01 (m, 2H), 4.27-3.86 (m, 4H), 3.28-3.13 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 148.24, 132.97, 130.75, 128.97, 127.74, 125.40, 124.54, 120.61, 51.26, 50.94, 48.22, 45.82. HRMS (*m/z*): calcd. for C₁₃H₁₄N₅OCl [M+H]⁺: 292.0960; found, 292.0958.

KK054-N1 (18): (4-(4-chlorophenyl)piperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone. KK054-N1 (**18**) was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 1-(4-chlorophenyl)piperazine (150 mg, 0.8 mmol), *N,N*-diisopropylethylamine (296 mg, 2.3 mmol), triphosgene (113 mg, 0.4 mmol) and THF (5 mL). Then KK054-N1 (**18**) (86 mg, 39%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (713 mg, 5.5 mmol), 1*H*-1,2,3-triazole (63 mg, 0.9 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.21 (d, *J* = 1.3 Hz, 1H), 7.75 (d, *J* = 1.3 Hz, 1H), 7.26-7.22 (m, 2H), 6.89-6.85 (m, 2H), 4.26-3.85 (m, 4H), 3.41-3.19 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 149.21, 148.00, 133.00, 129.16, 125.76, 125.43, 117.93, 49.58, 49.28, 47.67, 45.33. HRMS (*m/z*): calcd. for C₁₃H₁₄N₅OCl [M+H]⁺: 292.0960; found, 292.0960.

KK055-N1 (19): (4-(pyridin-2-yl)piperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone. KK055-N1 (**19**) was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 1-(2-pyridyl)piperazine (150 mg, 0.9 mmol), *N,N*-diisopropylethylamine (356 mg, 2.8 mmol), triphosgene (136 mg, 0.5 mmol) and THF (5 mL). Then KK055-N1 (**19**) (61 mg, 26%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (356 mg, 2.8 mmol), 1*H*-1,2,3-triazole (76 mg, 1.1 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.27-8.15 (m, 2H), 7.75 (d, *J* = 1.1 Hz, 1H), 7.57-7.51 (m, 1H), 6.73-6.65 (m, 2H), 4.25-3.83 (m, 4H), 3.83-3.61 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 158.79, 148.19, 148.03, 137.78, 133.00, 125.42, 114.21, 107.21, 47.53, 45.27, 44.73. HRMS (*m/z*): calcd. for C₁₂H₁₄N₆O [M+H]⁺: 259.1302; found, 259.1304.

KK067 (20): The mixture of (4-(4-nitrophenyl)piperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone (N1 isomer) and (4-(4-nitrophenyl)piperazin-1-yl)(2*H*-1,2,3-triazol-2-yl)methanone (N1 isomer). KK067 (**20**) was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 1-(4-nitrophenyl)piperazine (100 mg, 0.5 mmol), *N,N*-diisopropylethylamine (187 mg, 1.5 mmol), triphosgene (72 mg, 0.2 mmol) and THF (5 mL).

1172 Then the KK067-N1, N2 mixture (**20**) (97 mg, 66%; NMR ratio N1-isomer:N2-isomer = 6:4) was
 1173 obtained as a yellow solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-
 1174 diisopropylethylamine (187 mg, 1.5 mmol), 1*H*-1,2,3-triazole (40 mg, 0.6 mmol) and DMAP
 1175 (cat.).

1176 **KK067-N1**: ¹H NMR (500 MHz, CDCl₃): δ 8.24 (d, *J* = 1.3 Hz, 1H), 8.22-8.12 (m, 2H), 7.77 (d, *J*
 1177 = 1.3 Hz, 1H), 6.92-6.82 (m, 2H), 4.32-3.91 (m, 4H), 3.69-3.53 (m, 4H).

1178 **KK067-N2**: ¹H-NMR (500 MHz, CDCl₃): δ 8.22-8.12 (m, 2H), 7.87 (s, 2H), 6.92-6.82 (m, 2H),
 1179 4.32-3.91 (m, 4H), 3.69-3.53 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 154.26, 154.19, 148.86,
 1180 148.06, 139.40, 139.32, 136.46, 133.12, 125.94, 125.49, 113.15, 113.12, 106.46, 47.01. HRMS
 1181 (*m/z*): calcd. for C₁₃H₁₄N₆O₃ [M+H]⁺: 303.1200; found, 303.1201.

1182
 1183 **KK070 (21)**: The mixture of 4-(4-(1*H*-1,2,3-triazole-1-carbonyl)piperazin-1-yl)benzonitrile (N1-
 1184 isomer) and 4-(4-(2*H*-1,2,3-triazole-2-carbonyl)piperazin-1-yl)benzonitrile (N2-isomer).

1185 **KK070 (21)** was synthesized as the same method as compound **17**. The carbamoyl chloride
 1186 intermediate was obtained with 4-(1-piperazinyl)benzonitrile (150 mg, 0.8 mmol), *N,N*-
 1187 diisopropylethylamine (311 mg, 2.4 mmol), triphosgene (119 mg, 0.4 mmol) and THF (5 mL).
 1188 Then the KK070-N1, N2 mixture (**21**) (117mg, 52%; NMR ratio N1-isomer:N2-isomer = 87:12)
 1189 was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-
 1190 diisopropylethylamine (311 mg, 2.4 mmol), 1*H*-1,2,3-triazole (66 mg, 1.0 mmol) and DMAP
 1191 (cat.).

1192 **KK070-N1**: ¹H NMR (500 MHz, CDCl₃): δ 8.23 (d, *J* = 1.3 Hz, 1H), 7.76 (d, *J* = 1.3 Hz, 1H),
 1193 7.59-7.51 (2H, m), 6.94-6.87 (m, 2H), 4.30-3.88 (m, 4H), 3.59-3.43 (m, 4H).

1194 **KK070-N2**: ¹H-NMR (500 MHz, CDCl₃): δ 7.86 (s, 2H), 7.59-7.51 (m, 2H), 6.94-6.87 (m, 2H),
 1195 4.30-3.88 (m, 4H), 3.59-3.43 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 152.69, 148.00, 136.37,
 1196 133.60, 133.06, 125.45, 119.57, 114.64, 101.61, 47.22, 44.88. HRMS (*m/z*): calcd. for C₁₄H₁₄N₆O
 1197 [M+H]⁺: 283.1302; found, 283.1303.

1198
 1199 **KK071 (22)**: The mixture of (4-cyclohexylpiperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone (N1-
 1200 isomer) and (4-cyclohexylpiperazin-1-yl)(2*H*-1,2,3-triazol-2-yl)methanone (N2-isomer).

1201 **KK071 (22)** was synthesized as the same method as compound **17**. The carbamoyl chloride
 1202 intermediate was obtained with 1-cyclohexylpiperazine (150 mg, 0.9 mmol), *N,N*-
 1203 diisopropylethylamine (346 mg, 2.7 mmol), triphosgene (132 mg, 0.5 mmol) and THF (5 mL).
 1204 Then the KK071-N1, N2 mixture (**22**) (169 mg, 72%, NMR ratio N1-isomer:N2-isomer = 64:36)
 1205 was obtained as colorless oil with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-

diisopropylethylamine (346 mg, 2.7 mmol), 1*H*-1,2,3-triazole (74 mg, 1.1 mmol) and DMAP (cat.).

KK071-N1: ¹H-NMR (500 MHz, CDCl₃): δ 8.17 (d, *J* = 1.3 Hz, 1H), 7.73 (d, *J* = 1.3 Hz, 1H), 4.01-3.61 (m, 4H), 2.81-2.59 (m, 4H), 2.43-2.25 (m, 2H), 1.93-1.75 (m, 4H), 1.70-1.56 (m, 1H), 1.36-0.99 (m, 4H).

KK071-N2: ¹H-NMR (500 MHz, CDCl₃): δ 7.82 (s, 2H), 4.01-3.61 (m, 4H), 2.81-2.59 (m, 4H), 2.43-2.25 (m, 2H), 1.93-1.75 (m, 4H), 1.70-1.56 (m, 1H), 1.36-0.99 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 148.88, 147.96, 135.87, 132.84, 125.27, 63.46, 49.06, 48.39, 45.97, 28.81, 26.16, 25.73. HRMS (*m/z*): calcd. for C₁₃H₂₁N₅O [M+H]⁺: 264.1819; found, 264.1830.

KK072 (23): The mixture of (4-(*p*-tolyl)piperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone (N1-isomer) and (4-(*p*-tolyl)piperazin-1-yl)(2*H*-1,2,3-triazol-2-yl)methanone (N2-isomer) **KK072 (23)** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 1-(4-methylphenyl)piperazine (150 mg, 0.9 mmol), *N,N*-diisopropylethylamine (330 mg, 2.6 mmol), triphosgene (71 mg, 1.0 mmol) and THF (5 mL). Then the **KK072-N1, N2** mixture (**23**) (231 mg, quant, NMR ratio N1-isomer:N2-isomer = 69:31) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (330 mg, 2.6 mmol), 1*H*-1,2,3-triazole (71 mg, 1.0 mmol) and DMAP (cat.).

KK072-N1: ¹H NMR (500 MHz, CDCl₃): δ 8.20 (d, *J* = 1.1 Hz, 1H), 7.74 (d, *J* = 1.1 Hz, 1H), 7.13-7.09 (m, 2H), 6.90-6.84 (m, 2H), 4.25-3.80 (m, 4H), 3.45-3.10 (m, 4H), 2.29 (s, 3H).

KK072-N2: ¹H NMR (500 MHz, CDCl₃): δ 7.84 (s, 1H), 7.13-7.09 (m, 2H), 6.90-6.84 (m, 2H), 4.25-3.80 (m, 4H), 3.45-3.10 (m, 4H), 2.29 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 148.57, 148.47, 148.04, 136.11, 132.95, 130.48, 130.42, 129.80, 125.41, 117.09, 49.92, 47.74, 45.47, 20.42. HRMS (*m/z*): calcd. for C₁₄H₁₇N₅O [M+H]⁺: 272.1506; found, 272.1517.

KK073 (24): The mixture of (1*H*-1,2,3-triazol-1-yl)(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methanone (N1-isomer) and (2*H*-1,2,3-triazol-2-yl)(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methanone (N2-isomer). **KK073 (24)** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 1-(4-trifluoromethylphenyl)piperazine (150 mg, 0.7 mmol), *N,N*-diisopropylethylamine (253 mg, 2.0 mmol), triphosgene (97 mg, 0.3 mmol) and THF (5 mL). Then the **KK073-N1, N2** mixture (**24**) (188 mg, 89%, NMR ratio N1-isomer:N2-isomer = 73:17) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-

diisopropylethylamine (253 mg, 2.0 mmol), 1*H*-1,2,3-triazole (54 mg, 0.8 mmol) and DMAP (cat.).

KK073-N1: ¹H NMR (500 MHz, CDCl₃): δ 8.22 (d, *J* = 1.4 Hz, 1H), 7.76 (d, *J* = 1.4 Hz, 1H), 7.56-7.50 (m, 2H), 6.98-6.94 (m, 2H), 3.95-4.18 (m, 4H), 3.45-3.45 (m, 4H).

KK073-N2: ¹H NMR (500 MHz, CDCl₃): δ 7.86 (s, 1H), 7.56-7.50 (m, 2H), 6.98-6.94 (m, 2H), 4.18-3.95 (m, 4H), 3.56-3.32 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 152.72, 152.64, 148.90, 148.06, 136.31, 133.07, 127.74, 126.59, 125.59, 125.48, 123.44, 121.87, 115.18, 77.28, 77.03, 76.77, 48.31, 47.49, 45.12. HRMS (*m/z*): calcd. for C₁₄H₁₄N₅OF₃ [M+H]⁺: 326.1223; found, 326.1233.

KK075 (25): The mixture of (4-benzhydrylpiperazin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone (N1-isomer) and (4-benzhydrylpiperazin-1-yl)(2*H*-1,2,3-triazol-2-yl)methanone (N2-isomer). KK075 (25) was synthesized as the same method as compound 17. The carbamoyl chloride intermediate was obtained with 1-(diphenylmethyl)piperazine (150 mg, 0.6 mmol), *N,N*-diisopropylethylamine (230 mg, 1.8 mmol), triphosgene (97 mg, 0.3 mmol) and THF (5 mL). Then the KK075-N1, N2 mixture (25) (186 mg, 90%, NMR ratio N1-isomer:N2-isomer = 65:35) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (230 mg, 1.8 mmol), 1*H*-1,2,3-triazole (49 mg, 0.7 mmol) and DMAP (cat.).

KK075-N1: ¹H NMR (500 MHz, CDCl₃): δ 8.13 (d, *J* = 1.1 Hz, 1H), 7.69 (d, *J* = 1.1 Hz, 1H), 7.45-7.39 (m, 4H), 7.32-7.25 (m, 4H), 7.23-7.17 (2H), 4.31 (s, 1H), 4.07-3.55 (m, 4H), 2.69-2.36 (m, 4H).

KK075-N2: ¹H NMR (500 MHz, CDCl₃): δ 7.77 (s, 2H), 7.45-7.39 (m, 4H), 7.32-7.25 (m, 4H), 7.23-7.17 (2H), 4.29 (s, 1H), 4.07-3.55 (m, 4H), 2.69-2.36 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ 148.91, 148.01, 141.91, 141.76, 135.86, 132.84, 128.65, 127.83, 127.26, 127.22, 125.24, 75.84, 75.77, 51.83, 51.28, 47.92, 45.48. HRMS (*m/z*): calcd. for C₂₀H₂₁N₅O [M+H]⁺: 348.1819; found, 348.1834.

KK094 (26): The mixture of indolin-1-yl(1*H*-1,2,3-triazol-1-yl)methanone (N1-isomer) and indolin-1-yl(2*H*-1,2,3-triazol-2-yl)methanone (N2-isomer). KK094 (26) was synthesized as the same method as compound 17. The carbamoyl chloride intermediate was obtained with indoline (400 mg, 3.4 mmol), *N,N*-diisopropylethylamine (1.301 g, 10.1 mmol), triphosgene (498 mg, 1.7 mmol) and THF (5 mL). Then the KK094-N1, N2 mixture (26) (675 mg, 94%, NMR ratio N1-isomer:N2-isomer = 6:4) was obtained as a white solid with

the carbamoyl chloride intermediate, THF (10 mL), *N,N*-diisopropylethylamine (1.301 g, 10.1 mmol), 1*H*-1,2,3-triazole (49 mg, 0.7 mmol) and DMAP (cat.). Then the mixture was further purified on a silica gel column (Hexane:CH₂Cl₂:EtOAc = 1:4:0.4 to 0:4:0.4) giving KK094-N1 (190 mg, 26%) as a white solid and KK094-N2 (97 mg, 14%) as a white solid.

KK094-N1: ¹H NMR (500 MHz, CDCl₃): δ 8.36 (d, *J* = 1.1 Hz, 1H), 8.11 (br s, 1H), 7.78 (d, *J* = 1.1 Hz, 1H), 7.33-7.27 (m, 2H), 7.16 (t, *J* = 7.4 Hz, 1H), 4.67 (t, *J* = 8.3 Hz, 2H), 3.26 (t, *J* = 8.3 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 145.92, 141.88, 132.91, 132.19, 127.68, 125.45, 125.00, 124.96, 117.49, 51.77, 28.55. HRMS (*m/z*): calcd. for C₁₁H₁₀N₄O, [M+H]⁺: 215.0927; found, 215.0927.

KK094-N2: ¹H NMR (500 MHz, CDCl₃): δ 8.10 (s, 1H), 7.88 (s, 2H), 7.35-7.20 (m, 2H), 7.13 (t, *J* = 7.4 Hz, 1H), 4.47 (t, *J* = 8.3 Hz, 2H), 3.22 (t, *J* = 8.3 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 146.35, 141.95, 136.27, 132.03, 127.67, 125.04, 124.84, 117.48, 51.39, 28.45. HRMS (*m/z*): calcd. for C₁₁H₁₀N₄O [M+Na]⁺: 237.0747; found, 237.0757.

KK099 (27): The mixture of isoindolin-2-yl(1*H*-1,2,3-triazol-1-yl)methanone (N1-isomer) and isoindolin-2-yl(2*H*-1,2,3-triazol-2-yl)methanone (N2-isomer).

KK099 (27) was synthesized as the same method as compound 17. The carbamoyl chloride intermediate was obtained with isoindoline (200 mg, 1.7 mmol), *N,N*-diisopropylethylamine (651 mg, 5.0 mmol), triphosgene (249 mg, 0.9 mmol) and THF (5 mL). Then the KK099-N1, N2 mixture (27) (675 mg, 94%, NMR ratio N1-isomer:N2-isomer = 6:4) was obtained as a white solid with the carbamoyl chloride intermediate, THF (10 mL), *N,N*-diisopropylethylamine (651 mg, 5.0 mmol), 1*H*-1,2,3-triazole (116 mg, 2.0 mmol) and DMAP (cat.). Then the mixture was further purified on a silica gel column (Hexane:CH₂Cl₂:EtOAc = 1:4:0.4 to 0:4:0.4) giving KK099-N1 (93 mg, 26%) as a white solid and KK099-N2 (86 mg, 24%) as a white solid.

KK099-N1: ¹H NMR (500 MHz, CDCl₃): δ 8.36 (d, *J* = 1.1 Hz, 1H), 8.11 (br s, 1H), 7.78 (d, *J* = 1.1 Hz, 1H), 7.33-7.27 (m, 2H), 7.16 (t, *J* = 7.4 Hz, 1H), 4.67 (t, *J* = 8.3 Hz, 2H), 3.26 (t, *J* = 8.3 Hz, 2H). ¹H NMR (500 MHz, CDCl₃): δ 8.40 (d, *J* = 1.3 Hz, 1H), 7.77 (d, *J* = 1.3 Hz, 1H), 7.38-7.28 (m, 4H), 5.47 (s, 2H), 5.11 (s, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 147.1, 136.4, 134.0, 132.8, 128.0, 127.9, 124.9, 122.7, 122.6, 56.0, 55.1. HRMS (*m/z*): calcd. for C₁₁H₁₀N₄O, [M+H]⁺: 215.0927; found, 215.0920.

KK099-N2: ¹H NMR (500 MHz, CDCl₃): δ 7.89 (s, 2H), 7.37-7.24 (m, 5H), 5.31 (s, 2H), 5.13 (s, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 147.7, 136.4, 136.3, 134.6, 127.9, 127.8, 122.6, 122.5, 55.8, 55.0. HRMS (*m/z*): calcd. for C₁₁H₁₀N₄O [M+Na]⁺: 237.0747; found, 237.0749.

KK122 (28): (1*H*-imidazol-1-yl)(indolin-1-yl)methanone.
1,1'-carbonyldiimidazole (180 mg, 1.1 mmol) was added to the solution of indoline (100 mg, 0.8 mmol) in THF (5 mL) and stirred overnight at rt. Then the solvent was removed under vacuum and the resulting residue was dissolved in EtOAc and water and pH was adjusted to 7 with 0.5 M HCl, and extracted with EtOAc and water twice. The EtOAc layer was combined and the solvent was removed under vacuum and the resulting residue was purified on a silica gel column (EtOAc:MeOH = 1:0 to 9:1) giving **KK122 (28)** (147 mg, 82%) as a white solid.
¹H NMR (500 MHz, CDCl₃): δ 8.02 (m, 1H), 7.41 (br s, 1H), 7.36 (m, 1H), 7.26 (d, *J* = 7.5 Hz, 1H), 7.20 (t, *J* = 7.5 Hz, 1H), 7.13-7.13 (m, 1H), 7.09 (td, *J* = 7.5, 0.8 Hz, 1H), 4.19 (t, *J* = 8.2 Hz, 2H), 3.20 (t, *J* = 8.2 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 148.16, 141.30, 136.58, 131.91, 129.81, 127.56, 125.07, 124.87, 117.45, 116.44, 50.97, 28.30.

Compound 29: (2-methylindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.
Compound **29** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 2-methylindoline (300 mg, 2.3 mmol), *N,N*-diisopropylethylamine (2.08 g, 16.1 mmol), triphosgene (267 mg, 0.9 mmol) and THF (5 mL). Then the compound **29** (55 mg, 11%) was obtained as colorless oil with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (873 mg, 6.8 mmol), 1*H*-1,2,3-triazole (187 mg, 2.7 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.35 (d, *J* = 1.1 Hz, 1H), 8.09 (br s, 1H), 7.78 (d, *J* = 1.1 Hz, 1H), 7.38-7.27 (m, 2H), 7.17 (t, *J* = 7.2 Hz, 1H), 5.70 (m, 1H), 3.53 (dd, *J* = 15.5, 9.2 Hz, 1H), 2.78 (d, *J* = 15.5 Hz, 1H), 1.27 (d, *J* = 6.3 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 145.76, 140.88, 132.87, 131.29, 127.69, 125.54, 125.67, 125.13, 118.00, 58.43, 36.47, 21.56. HRMS (*m/z*): calcd. for C₁₂H₁₂N₄O [M+Na]⁺: 251.0903; found, 251.904.

Compound 30: (3-methylindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.
Compound **30** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 3-methylindoline (713 mg, 5.4 mmol), *N,N*-diisopropylethylamine (2.08 g, 16.1 mmol), triphosgene (635 mg, 2.1 mmol) and THF (5 mL). Then the compound **30** (509 mg, 42%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (2.08 g, 16.1 mmol), 1*H*-1,2,3-triazole (187 mg, 2.7 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.37 (d, *J* = 1.1 Hz, 1H), 8.09 (br s, 1H), 7.78 (d, *J* = 1.1 Hz, 1H), 7.35-7.22 (m, 2H), 7.19 (t, *J* = 7.4 Hz, 1H), 4.82 (dd, *J* = 11.5, 9.7 Hz, 1H), 4.22 (dd, *J* = 11.5, 6.9 Hz, 1H), 3.62-3.51 (m, 1H), 1.39 (d, *J* = 6.9 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 145.81, 141.43, 137.37, 132.92, 127.85, 125.60, 124.97, 123.81, 117.38, 59.55, 35.28,

19.64. HRMS (m/z): calcd. for C₁₂H₁₂N₄O [M+H]⁺: 229.1084; found, 229.1085.

Compound 31: (4-nitroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **31** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 4-nitroindoline (837 mg, 5.1 mmol), *N,N*-diisopropylethylamine (1.98 g, 15.3 mmol), triphosgene (605 mg, 2.0 mmol) and THF (5 mL). Then the compound **31** (64 mg, 5%) was obtained as a yellow solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (1.98 g, 15.3 mmol), 1*H*-1,2,3-triazole (423 mg, 6.1 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.45 (br s, 1H), 8.39 (d, *J* = 1.1 Hz, 1H), 8.02 (d, *J* = 8.3 Hz, 1H), 7.81 (d, *J* = 1.1 Hz, 1H), 7.51 (t, *J* = 8.3 Hz, 1H), 4.80 (t, *J* = 8.4 Hz, 2H), 3.77 (t, *J* = 8.4 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 146.34, 145.26, 144.67, 133.19, 129.57, 129.12, 125.10, 122.82, 120.54, 52.08, 29.78. HRMS (m/z): calcd. for C₁₁H₉N₅O₃ [M+H]⁺: 260.0778; found, 260.0781.

Compound 32: (4-chloroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **32** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 4-chloroindoline (1.00 g, 6.5 mmol), *N,N*-diisopropylethylamine (2.52 g, 19.5 mmol), triphosgene (773 mg, 2.6 mmol) and THF (5 mL). Then the compound **32** (47 mg, 3%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (2.52 g, 19.5 mmol), 1*H*-1,2,3-triazole (540 mg, 7.8 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.36 (d, *J* = 1.1 Hz, 1H), 8.01 (br s, 1H), 7.78 (d, *J* = 1.1 Hz, 1H), 7.28-7.22 (m, 2H), 7.15 (d, *J* = 7.4 Hz, 1H), 4.72 (t, *J* = 8.3 Hz, 2H), 3.28 (t, *J* = 8.3 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 146.03, 143.22, 136.51, 133.00, 130.88, 129.18, 125.34, 125.02, 115.72, 51.63, 28.05. HRMS (m/z): calcd. for C₁₁H₉N₄OCl [M+H]⁺: 249.0538; found, 249.0538.

Compound 33: (4-methylindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **33** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 4-methylindoline (730 mg, 5.5 mmol), *N,N*-diisopropylethylamine (2.13 g, 16.4 mmol), triphosgene (651 mg, 2.2 mmol) and THF (5 mL). Then the compound **33** (423 mg, 34%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (2.13g, 16.4mmol), 1*H*-1,2,3-triazole (454 mg, 6.6 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.36 (d, *J* = 1.1 Hz, 1H), 7.95 (br s, 1H), 7.77 (d, *J* = 1.1 Hz, 1H), 7.21 (t, *J* = 7.7 Hz, 1H), 6.99 (d, *J* = 7.4 Hz, 1H), 4.68 (t, *J* = 8.2 Hz, 2H), 3.15 (t, *J* =

8.2 Hz, 2H), 2.29 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ 145.91, 141.60, 134.48, 132.87, 130.96, 127.81, 126.40, 124.95, 114.90, 51.68, 27.46, 18.62. HRMS (*m/z*): calcd. for C₁₂H₁₂N₄O, [M+Na]⁺: 251.0903; found, 251.0907.

Compound 34: (5-nitroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **34** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 5-nitroindoline (1.00 g, 6.1 mmol), *N,N*-diisopropylethylamine (2.36 g, 18.3 mmol), triphosgene (723 mg, 2.4 mmol) and THF (5 mL). Then the compound **34** (143 mg, 9%) was obtained as a yellow solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (2.36 g, 18.3 mmol), 1*H*-1,2,3-triazole (505 mg, 7.3 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.40 (d, *J* = 1.3 Hz, 1H), 8.26-8.19 (m, 2H), 8.16 (t, *J* = 1.4 Hz, 1H), 7.81 (d, *J* = 1.1 Hz, 1H), 4.84 (t, *J* = 8.5 Hz, 2H), 3.38 (t, *J* = 8.5 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 147.65, 146.31, 145.04, 133.61, 133.26, 125.22, 124.44, 120.61, 117.25, 52.64, 28.12. HRMS (*m/z*): calcd. for C₁₁H₉N₅O₃ [M+Na]⁺: 282.0598; found, 282.0596.

Compound 35: (5-chloroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **35** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 5-chloroindoline (1.00 g, 6.5 mmol), *N,N*-diisopropylethylamine (2.52 g, 19.5 mmol), triphosgene (773 mg, 2.6 mmol) and THF (5 mL). Then the compound **35** (450 mg, 28%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (2.52 g, 19.5 mmol), 1*H*-1,2,3-triazole (540 mg, 7.8 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.36 (d, *J* = 1.1 Hz, 1H), 8.04 (br s, 1H), 7.77 (d, *J* = 1.1 Hz, 1H), 4.70 (t, *J* = 8.3 Hz, 2H), 3.25 (t, *J* = 8.3 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 145.88, 140.65, 134.03, 132.98, 130.51, 127.73, 125.17, 124.99, 118.39, 51.95, 28.37. HRMS (*m/z*): calcd. for C₁₁H₉N₄OCl [M+H]⁺: 249.0538; found, 249.0538.

Compound 35: (5-chloroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **35** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 5-chloroindoline (1.00 g, 6.5 mmol), *N,N*-diisopropylethylamine (2.52 g, 19.5 mmol), triphosgene (773 mg, 2.6 mmol) and THF (5 mL). Then the compound **35** (450 mg, 28%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (2.52 g, 19.5 mmol), 1*H*-1,2,3-triazole (540 mg, 7.8 mmol) and DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.36 (d, *J* = 1.1 Hz, 1H), 8.04 (br s, 1H), 7.77 (d, *J* = 1.1 Hz, 1H), 4.70 (t, *J* = 8.3 Hz, 2H), 3.25 (t, *J* = 8.3 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ

145.88, 140.65, 134.03, 132.98, 130.51, 127.73, 125.17, 124.99, 118.39, 51.95, 28.37. HRMS (m/z): calcd. for $C_{11}H_9N_4OCl$ $[M+H]^+$: 249.0538; found, 249.0538.

Compound 36: (5-methylindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **36** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 5-methylindoline (300 mg, 2.3 mmol), *N,N*-diisopropylethylamine (873 mg, 6.8 mmol), triphosgene (334 mg, 1.1 mmol) and THF (5 mL). Then the compound **35** (90 mg, 18%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (873 mg, 6.8 mmol), 1*H*-1,2,3-triazole (187 mg, 2.7 mmol) and DMAP (cat.). 1H NMR (500 MHz, $CDCl_3$): δ 8.35 (d, J = 1.1 Hz, 1H), 7.99 (br s, 1H), 7.76 (d, J = 1.1 Hz, 1H), 7.14-7.05 (m, 2H), 4.65 (t, J = 8.3 Hz, 2H), 3.21 (t, J = 8.3 Hz, 2H), 2.36 (s, 3H). ^{13}C NMR (125 MHz, $CDCl_3$): δ 145.72, 139.54, 135.32, 132.84, 132.25, 128.18, 125.60, 124.90, 117.15, 51.84, 28.50, 21.04. HRMS (m/z): calcd. for $C_{12}H_{12}N_4O$ $[M+Na]^+$: 251.0903; found, 251.0910.

Compound 37: (6-nitroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **37** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 6-nitroindoline (1.00 g, 6.1 mmol), *N,N*-diisopropylethylamine (2.36 g, 18.3 mmol), triphosgene (723 mg, 2.4 mmol) and THF (5 mL). Then the compound **37** (531 mg, 34%) was obtained as a yellow solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (2.36 g, 18.3 mmol), 1*H*-1,2,3-triazole (505 mg, 7.3 mmol) and DMAP (cat.). 1H NMR (500 MHz, $CDCl_3$): δ 8.94 (br s, 1H), 8.42 (d, J = 1.1 Hz, 1H), 8.06 (dd, J = 8.2, 2.0 Hz, 1H), 7.80 (d, J = 1.1 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 4.85 (t, J = 8.3 Hz, 2H), 3.38 (t, J = 8.3 Hz, 2H). ^{13}C NMR (125 MHz, $CDCl_3$): δ 148.03, 146.07, 143.21, 139.34, 133.17, 125.20, 125.12, 120.91, 112.74, 52.38, 28.62. HRMS (m/z): calcd. for $C_{11}H_9N_5O_3$ $[M+H]^+$: 260.0778; found, 260.0780.

Compound 38: (6-chloroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **38** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 6-chloro-2,3-dihydro-1*H*-indole (376 mg, 2.5 mmol), *N,N*-diisopropylethylamine (949mg, 7.3mmol), triphosgene (291 mg, 1.0 mmol) and THF (5 mL). Then the compound **38** (164 mg, 27%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (949mg, 7.3mmol), 1*H*-1,2,3-triazole (203 mg, 2.9 mmol) and DMAP (cat.). 1H NMR (500 MHz, $CDCl_3$): δ 8.37 (d, J = 1.3 Hz, 1H), 8.14

(br s, 1H), 7.78 (d, $J = 1.3$ Hz, 1H), 7.19 (d, $J = 8.0$ Hz, 1H), 7.13 (dd, $J = 8.0, 1.7$ Hz, 1H), 4.72 (t, $J = 8.3$ Hz, 2H), 3.23 (t, $J = 8.3$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3): δ 145.92, 143.09, 133.34, 133.01, 130.60, 125.60, 125.46, 125.07, 117.93, 52.37, 28.14. HRMS (m/z): calcd. for $\text{C}_{11}\text{H}_9\text{N}_4\text{OCl}$ $[\text{M}+\text{H}]^+$: 249.0538; found, 249.0541.

Compound 39: (6-methylindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **39** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 6-methylindoline (149 mg, 1.1 mmol), *N,N*-diisopropylethylamine (434 mg, 3.4 mmol), triphosgene (133 mg, 0.4 mmol) and THF (5 mL). Then the compound **38** (164 mg, 27%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-diisopropylethylamine (434 mg, 3.4 mmol), 1*H*-1,2,3-triazole (93 mg, 1.3 mmol) and DMAP (cat.). ^1H NMR (500 MHz, CDCl_3): δ 8.35 (d $J = 1.1$ Hz, 1H), 7.94 (br s, 1H), 7.70 (d, $J = 1.1$ Hz, 1H), 7.16 (d, $J = 7.5$ Hz, 1H), 6.97 (d, $J = 7.5$ Hz, 1H), 4.65 (t, $J = 8.5$ Hz, 2H), 3.16 (t, $J = 8.5$ Hz, 2H), 2.40 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ 145.88, 141.99, 137.70, 132.88, 129.23, 126.21, 124.92, 124.58, 118.09, 52.13, 28.21, 21.62. HRMS (m/z): calcd. for $\text{C}_{12}\text{H}_{12}\text{N}_4\text{O}$ $[\text{M}+\text{Na}]^+$: 251.0903; found, 251.0907.

Compound 40: (7-nitroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **40** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 7-nitroindoline (929 mg, 5.7 mmol), *N,N*-diisopropylethylamine (2.19 g, 17.0 mmol), triphosgene (672 mg, 2.3 mmol) and THF (15 mL). Then the compound **40** (51 mg, 3%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (15 mL), *N,N*-diisopropylethylamine (2.19 g, 17.0 mmol), 1*H*-1,2,3-triazole (469 mg, 6.8 mmol) and DMAP (cat.). ^1H NMR (500 MHz, CDCl_3): δ 8.31 (d, $J = 1.1$ Hz, 1H), 7.82 (dd, $J = 7.7, 1.1$ Hz, 1H), 7.77 (d, $J = 1.1$ Hz, 1H), 7.55 (dd, $J = 7.4, 1.1$ Hz, 1H), 7.30 (t, $J = 7.7$ Hz, 1H), 4.68 (t, $J = 8.0$ Hz, 2H), 3.31 (t, $J = 8.0$ Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3): δ 147.36, 140.40, 136.95, 134.62, 133.47, 129.59, 126.03, 124.79, 123.36, 54.26, 29.42. HRMS (m/z): calcd. for $\text{C}_{11}\text{H}_9\text{N}_5\text{O}_3$ $[\text{M}+\text{Na}]^+$: 282.0598; found, 282.0602.

Compound 41: (7-chloroindolin-1-yl)(1*H*-1,2,3-triazol-1-yl)methanone.

Compound **41** was synthesized as the same method as compound **17**. The carbamoyl chloride intermediate was obtained with 7-chloroindoline (713 mg, 4.6 mmol), *N,N*-diisopropylethylamine (1.80 g, 13.9 mmol), triphosgene (551 mg, 1.9 mmol) and THF (5 mL). Then the compound **40** (587 mg, 51%) was obtained as a white solid with the carbamoyl chloride intermediate, THF (5

1478 mL), *N,N*-diisopropylethylamine (1.80 g, 13.9 mmol), 1*H*-1,2,3-triazole (385 mg, 5.6 mmol) and
1479 DMAP (cat.). ¹H NMR (500 MHz, CDCl₃): δ 8.34 (d, *J* = 1.1 Hz, 1H), 7.78 (d, *J* = 1.1 Hz, 1H),
1480 7.28 (d, *J* = 7.4 Hz, 1H), 7.22 (dd, *J* = 7.4, 1.1 Hz, 1H), 7.14 (t, *J* = 7.7 Hz, 1H), 4.46 (t, *J* = 7.7
1481 Hz, 2H), 3.20 (t, *J* = 7.7 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 146.32, 139.04, 136.70, 133.40,
1482 129.30, 127.11, 124.48, 124.29, 123.26, 54.94, 30.50. HRMS (*m/z*): calcd. for C₁₁H₉N₄OCl
1483 [M+Na]⁺: 271.0357; found, 271.0362.

1484

1485 **KK182 (42)**: The mixture of (1*H*-1,2,3-triazol-1-yl)(4-(4-(trifluoromethyl)benzyl)piperazin-1-
1486 yl)methanone (N1-isomer) and (2*H*-1,2,3-triazol-1-yl)(4-(4-(trifluoromethyl)benzyl)piperazin-1-
1487 yl)methanone (N2-isomer).

1488 **KK182 (42)** was synthesized as the same method as compound **17**. The carbamoyl chloride
1489 intermediate was obtained with 1-(4-trifluoromethylbenzyl)piperazine (1 g, 4.1 mmol), *N,N*-
1490 diisopropylethylamine (1.59 g, 12.3 mmol), triphosgene (486 mg, 1.6 mmol) and THF (5 mL).
1491 Then the compound **42** with the carbamoyl chloride intermediate, THF (5 mL), *N,N*-
1492 diisopropylethylamine (1.59 g, 12.3 mmol), 1*H*-1,2,3-triazole (339 mg, 4.9 mmol) and DMAP
1493 (cat.). Then the mixture was further purified on a silica gel column (Hexane:CH₂Cl₂:EtOAc =
1494 1:4:0.4 to 0:4:0.4) giving KK182-N1 (260 mg, 19%) as a white solid and KK094-N2 (97 mg,
1495 14%) as a white solid.

1496 **KK 182-N1**: ¹H -NMR (500 MHz, CDCl₃) δ 8.18 (d, *J* = 1.3 Hz, 1H), 7.73 (d, *J* = 1.3 Hz, 1H),
1497 7.60 (d, *J* = 8.1 Hz, 2H), 7.47 (d, *J* = 8.1 Hz, 2H), 4.10-3.71 (m, 4H), 3.62 (d, *J* = 5.3 Hz, 2H),
1498 2.71-2.49 (m, 4H). ¹³C -NMR (126 MHz, CDCl₃) δ 148.05, 141.61, 132.91, 129.67(q, *J* = 32.4
1499 Hz), 129.16, 125.36, 125.32, 124.11(q, *J* = 271.8 Hz), 62.07, 52.98, 52.39, 47.86, 45.53. HRMS
1500 (*m/z*): calcd. for C₁₅H₁₆N₅OF₃ [M+H]⁺: 340.1380; found, 340.1392.

1501 **KK 182-N2**: ¹H -NMR (500 MHz, CDCl₃) δ 7.81 (s, 2H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.47 (d, *J* =
1502 8.0 Hz, 2H), 3.95-3.64 (4H), 3.61 (s, 2H), 2.72-2.37 (m, 4H). ¹³C -NMR (126 MHz, CDCl₃) δ
1503 148.95, 141.77, 136.01, 129.64 (q, *J* = 32.4 Hz), 129.13, 125.32 (q, *J* = 3.8 Hz), 124.13 (q, *J* =
1504 272.8 Hz), 62.11, 52.74, 47.67, 45.28. HRMS (*m/z*): calcd. for C₁₅H₁₆N₅OF₃ [M+H]⁺: 340.1380;
1505 found, 340.1390.

1506

1507